Document:

<PAGE>
                                                                   Exhibit 10.54

                   BOTOX(R) GLOBAL STRATEGIC SUPPORT AGREEMENT

                                 BY AND BETWEEN

                              GLAXO GROUP LIMITED,

                                 ALLERGAN, INC.

                                       AND

                               ALLERGAN SALES, LLC

                               SEPTEMBER 30, 2005

<PAGE>

                   BOTOX(R) GLOBAL STRATEGIC SUPPORT AGREEMENT

     THIS BOTOX(R) GLOBAL STRATEGIC SUPPORT AGREEMENT, including the exhibits
referred to herein and attached hereto (collectively, the "AGREEMENT") is made
and entered into effective as of September 30, 2005 (the "EFFECTIVE DATE"), by
and between ALLERGAN, INC., a Delaware corporation, having its principal place
of business at 2525 Dupont Drive, Irvine, California 92612, U.S.A., ALLERGAN
SALES, LLC, a Delaware limited liability company, having its principal place of
business at 2525 Dupont Drive, Irvine, California 92612, U.S.A. (ALLERGAN, INC.
and ALLERGAN SALES, LLC are collectively referred to herein as "ALLERGAN") and
GLAXO GROUP LIMITED, a private limited company incorporated in England and
Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex, England UB6 0NN ("GSK").

                                    RECITALS

     WHEREAS, ALLERGAN and GSK desire to build the image, awareness and
effectiveness of the BOTOX(R) brand in the Territory (as defined below).

     NOW, THEREFORE, in consideration of the mutual covenants and obligations
set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, ALLERGAN and GSK hereby agree as
follows:

                                    AGREEMENT

1.   DEFINITIONS

     1.1 "AFFILIATE" of a Party or Person means any Person, whether de jure or
de facto, that directly or indirectly, controls, is controlled by, or is under
common control with such Party or Person, as applicable. Solely as used in this
definition, "control" means (a) direct or indirect ownership of more than fifty
percent (50%) of the equity (or such lesser percentage which is the maximum
allowed to be owned by a foreign corporation in a particular jurisdiction)
having the power to vote on or direct the affairs of such Party or Person, as
applicable, or (b) the possession, directly or indirectly, of the power to
direct or cause the direction of the policies and management of such Party or
Person, as applicable, whether by the ownership of stock, by contract, or
otherwise.

     1.2 "AGREEMENT" will have the meaning set forth in the Preamble.

     1.3 "ALLERGAN" will have the meaning set forth in the Preamble.

     1.4 "APPLICABLE LAW" means all applicable provisions of any and all
federal, national, state, provincial, and local statutes, laws, rules,
regulations, administrative codes, ordinances, decrees, orders, decisions,
injunctions, awards, judgments, permits and licenses of or from any governmental
authorities relating to or governing the use or regulation of the subject item
or action.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       1

<PAGE>

     1.5 "BOTOX" means any pharmaceutical composition intended for
administration to humans containing botulinum toxin type A, regardless of
formulation, dosage, or form, which is marketed by ALLERGAN or GSK under the
BOTOX trademark.

     1.6 "CALENDAR YEAR" means, for the first Calendar Year, the period
beginning on the Execution Date and ending December 31, 2005, and for each
Calendar Year thereafter, each successive period beginning on January 1 and
ending twelve (12) consecutive calendar months later on December 31; provided
however, that the last Calendar Year of the Term may be for a term of less than
twelve (12) consecutive months.

     1.7 "EFFECTIVE DATE" will have the meaning set forth in the Preamble.

     1.8 "GLOBAL MARKETING" means ALLERGAN's BOTOX Global Strategic Marketing
team, which is responsible for determining long-term strategy, competitor and
trademark defense, global market research strategy, commercial assessment and
guidance of development projects, global publicity strategy, medical marketing
prioritization, publications and other strategic communications for BOTOX.

     1.9 "GSK" will have the meaning set forth in the Preamble.

     1.10 "PARTY" means either GSK or ALLERGAN and "Parties means both of them.

     1.11 "PERSON" means an individual, corporation, partnership, association,
trust or any other entity or organization, including, without limitation any
government or political subdivision or any agency or instrumentality thereof.

     1.12 "SEMI-ANNUAL PROGRESS REPORT" will have the meaning set forth in
Section 2.2.

     1.13 "SUPPORT SERVICES" will have the meaning set forth in Section 2.1.

     1.14 "TERM" will have the meaning set forth in Section 6.1.

     1.15 "TERRITORY" means Japan and the Peoples Republic of China, and their
respective territories and possessions; provided, however that Territory does
not include Hong Kong or Taiwan.

     1.16 "THIRD PARTY" means any Person other than ALLERGAN or GSK or either of
their respective Affiliates.

2.   SUPPORT ACTIVITIES

     2.1 General. ALLERGAN's objectives under this Agreement will be to (i)
assist GSK to develop scientifically differentiated and customer-responsive
promotional platforms and provide proactive strategic guidance to augment
development of effective promotional and medical education efforts for BOTOX in
the Territory, (ii) review whether tactical plans for BOTOX in the Territory
achieve consistency with worldwide BOTOX strategies, and (iii) assist GSK to
maintain synergy and/or best practices with respect to BOTOX marketing in the
Territory. In furtherance of

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                        2

<PAGE>

these objectives, during the Term and subject to the terms and conditions of
this Agreement, ALLERGAN or its Affiliates will use commercially reasonable
efforts to conduct the specific activities and deliver the deliverables set
forth on Exhibit A with respect to BOTOX (the "SUPPORT SERVICES").

     2.2 Semi-Annual Reports. Not later than July 31 and January 31 of each
Calendar Year, ALLERGAN will provide GSK with a written report detailing the
Support Services performed by ALLERGAN or its Affiliate during the immediately
preceding six (6) month period ending June 30 and December 31, respectively, and
the Support Services planned for the immediately succeeding (6) month periods,
including at a minimum a summary of the progress towards completion of the
Support Services ("SEMI-ANNUAL PROGRESS REPORTS").

     2.3. No Asset Transfer. Nothing in this Agreement will be construed as an
assignment, license or other transfer of ownership of any kind by either Party
of such Party's (or its Affiliates') intellectual property or other intangibles.

     2.4 Lead Contact. Each Party will appoint a lead contact to coordinate and
manage the Support Services ("LEAD CONTACT"). The Lead Contact for each Party
will be identified to the other Parties within ten (10) calendar days after the
Effective Date. Either Party may change its Lead Contact upon written notice to
the other Party.

3.   SUPPORT PAYMENTS

     3.1 Semi-annual Payments. In consideration for ALLERGAN's provision of the
Support Services as provided in this Agreement and subject to Sections 3.3, 3.4
and 3.5, GSK shall pay ALLERGAN in arrears on an semi-annual basis the amount
for such Calendar Year set forth in Exhibit B. Such amounts shall be paid by GSK
within forty-five (45) calendar days of GSK's receipt of the Semi-Annual
Progress Report and an invoice referring to this Support Agreement and
specifying the amount due; provided, however, that the final semi-annual payment
shall be due on the expiration date of Term.

     3.2 Records; Audit Right. ALLERGAN shall maintain records sufficient to
enable accurate calculation of the costs and expenses incurred by ALLERGAN in
providing the Support Services. ALLERGAN shall permit an independent public
accountant designated by GSK and reasonably acceptable to ALLERGAN, to have
access, no more than once in each Calendar Year during the Term and no more than
once following the expiration or termination of the Term, during regular
business hours and upon at least thirty (30) days' written notice, to examine in
confidence ALLERGAN's records solely to the extent necessary to determine that
*** with respect to such Calendar Year. The independent public accountant shall
not report to GSK anything other than whether *** with respect to such Calendar
Year. The costs and expense incurred by ALLERGAN in providing the Support
Services shall not be otherwise subject to audit or review by GSK or to any
report by the independent public accountant performing any audit or review
permitted by this Section. The costs of such review or audit shall be at GSK's
expense.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                        3

<PAGE>

     3.3 Performance Condition. GSK's obligation to pay ALLERGAN as provided in
Section 3.1 is subject to ALLERGAN (i) submitting the Semi-Annual Progress
Reports as provided in Section 2.2 that provide evidence to GSK that the Support
Services outlined on Exhibit A have been performed within the time periods set
forth on Exhibit A and (ii) for the payment to be made for the first half of any
Calendar Year, submitting a letter from ALLERGAN's Lead Contact confirming that
*** with respect to such period, and for the payment to be made at the end of
any Calendar Year, a letter from ALLERGAN's Lead Contact confirming that ***
with respect to such Calendar Year. If the foregoing documents are delivered
evidencing that the Support Services have been performed from semi-annual period
to semi-annual period as set forth and in accordance with the time periods set
forth in the Semi-Annual Progress Reports, ALLERGAN will have met its
performance condition.

     3.4 Taxes. To the extent a statutory tax withholding obligation is imposed
by a governmental authority upon any payment due and payable by GSK to ALLERGAN
under the terms and conditions of this Agreement, GSK will be entitled to
withhold from such payment the amount, if any, of any tax assessed against
ALLERGAN and actually withheld, provided that such tax is only for the account
of ALLERGAN and evidence of the payment of such tax is promptly provided to
ALLERGAN. GSK will pay the amount of such tax to the proper taxing authority and
will be entitled to deduct the amount of such tax from the payment to be made by
GSK to ALLERGAN. GSK will advise ALLERGAN of any tax payment made for the
benefit of ALLERGAN pursuant to this Section 3.4 and provide ALLERGAN copies of
tax receipts for all taxes paid and deducted from the payment due and payable to
ALLERGAN, together with copies of all pertinent communications from or with
governmental authorities with respect thereto. At ALLERGAN's reasonable request
and subject to ALLERGAN reimbursing any costs and expenses, GSK will reasonably
assist ALLERGAN in any effort by ALLERGAN in claiming any exemption from such
deductions or withholdings under any double taxation or similar agreement or
treaty from time to time in force, and in minimizing the amount required to be
so withheld or deducted. ALLERGAN warrants that ALLERGAN is resident for tax
purposes in United States of America and that ALLERGAN is entitled to relief
from United Kingdom income tax under the terms of the double tax agreement
between the United Kingdom and the United States of America. ALLERGAN will
notify GSK immediately in writing in the event that ALLERGAN ceases to be
entitled to such relief. Pending receipt of formal certification from the United
Kingdom Inland Revenue, GSK may pay any payments under this Agreement to
ALLERGAN by deducting tax at a rate specified in the double tax treaty between
the United Kingdom and the United States of America. ALLERGAN agrees to
indemnify and hold harmless GSK against any loss, damage, expense, or liability
arising in any way from a breach by ALLERGAN of the warranties in this Section
3.4 or any future claim by a United Kingdom tax authority or other similar body
alleging that GSK was not entitled to deduct such withholding tax on such
payments at source at the treaty rate.

     3.5 Payments Made in U.S. Currency; Wire Transfers. All payments made under
this Agreement will be made in U.S. dollars and payments made by GSK hereunder
will be made to ALLERGAN by bank wire transfer in immediately available funds to
ALLERGAN in accordance with the wire instructions set forth in Exhibit C, which
may be changed only by written notice to GSK from the Chief Financial Officer of
ALLERGAN in accordance with Section 8.7.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       4

<PAGE>

     3.6 Late Payments. Any payment due and payable under the terms and
conditions of this Agreement made by GSK or ALLERGAN after the date such payment
is due and payable, will bear interest as of the day after the date such payment
was due and payable, and will continue to accrue such interest until such
payment is made, at rate equal to *** per month. The payment of such interest
will not limit either Party from exercising any other rights it may have as a
consequence of the lateness of any payment.

4.   REPRESENTATIONS AND WARRANTIES; RESTRICTIVE COVENANTS

     4.1 By ALLERGAN. ALLERGAN represents and warrants that as of the Effective
Date:

          4.1.1 ALLERGAN is a corporation duly organized, validly existing, and
in good standing under the laws of the state of Delaware;

          4.1.2 The execution, delivery, and performance of this Agreement by
ALLERGAN have been duly authorized by all requisite corporate action and do not
require any shareholder action or approval;

          4.1.3 The execution, delivery, and performance by ALLERGAN of this
Agreement and its compliance with the terms and provisions hereof do not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (a) any agreement with a Third Party, including
but not limited to a loan agreement, guaranty, financing agreement, agreement
affecting a Product, or other agreement or instrument binding or affecting it or
its property; (b) the provisions of its charter or operative documents or
bylaws; or (c) any order, writ, injunction, or decree of any court or
governmental authority entered against it or by which any of its property is
bound; and

          4.1.4 ALLERGAN has the right and authority to provide the Support
Services to GSK and its Affiliates pursuant to the terms and conditions set
forth in this Agreement in the Territory.

     4.2 By GSK. GSK represents and warrants that as of the Effective Date:

          4.2.1 GSK is a private limited company duly organized, validly
existing, and in good standing under the laws England and Wales;

          4.2.2 The execution, delivery, and performance of this Agreement by
GSK has been duly authorized by all requisite corporate action and does not
require any shareholder action or approval; and

          4.2.3 The execution, delivery, and performance by GSK of this
Agreement and its compliance with the terms and provisions hereof does not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (a) a loan agreement, guaranty, financing
agreement, agreement affecting a Product, or other agreement or instrument
binding or affecting it or its property; (b) the provisions of its charter or
operative documents or

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                        5

<PAGE>

bylaws; or (c) any order, writ, injunction, or decree of any court or
governmental authority entered against it or by which any of its property is
bound.

     4.3 Disclaimer. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS
ARTICLE 4 ARE THE EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE IN OR UNDER THIS
SUPPORT AGREEMENT AND ARE IN LIEU OF ALL WARRANTIES, EXPRESS, STATUTORY OR
IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

     4.4 Restrictive Covenant of GSK.

          4.4.1 The Parties acknowledge that:

               (a) As of the Effective Date, neither GSK nor its Affiliates have
any current or future intention of making, having made, using, offer for sale or
importing a Competing Product (as defined in Section 4.4.2) in the Field of Use
in any country of the world; and

               (b) During the Term, GSK will obtain certain Confidential
Information of ALLERGAN relating to the development, manufacture and
commercialization of BOTOX, which is valuable and highly confidential to
ALLERGAN and critical to the competitive success of ALLERGAN's business
worldwide.

          4.4.2 To the extent permitted under Applicable Law, during the Term
and for a period of *** after the expiration date of this Agreement or the
effective date of the termination of this Agreement for any reason other than by
GSK pursuant to Sections 6.3.1 or 6.3.2 (the "RESTRICTIVE PERIOD"), neither GSK
nor any Affiliate of GSK will manufacture, market, distribute, sell, promote, or
detail any pharmaceutical product in the Territory, which ***, other than BOTOX
(a "COMPETING PRODUCT") in the Field of Use; provided, however, that:

               (a) If GSK or any of its Affiliates manufactures, initiates
clinical studies, markets, distributes, sells, promotes, or details
(collectively, "COMMERCIALIZATION") a Competing Product in *** during the Term,
GSK will (i) notify ALLERGAN immediately upon becoming aware of such
commercialization, and (ii) cease commercialization of such Competing Product
within *** after the date that GSK became aware of such commercialization. If
GSK does not cease such commercialization within *** after becoming aware of
such commercialization, ALLERGAN, at any time thereafter, will have a right to
terminate this Agreement or any other agreement between the Parties relating to
BOTOX in the Territory, which termination of this Agreement by ALLERGAN will be
deemed a termination by ALLERGAN pursuant to Section 6.3.1. During the period
between the date that GSK becomes aware of commercialization of a Competing
Product as provided in this Section 4.4.2(a) and the earlier of the date on
which GSK ceases such commercialization and the expiration of the Restrictive
Period, GSK will pay to ALLERGAN *** of all of GSK's or its Affiliates' net
sales of such Competing Product (which net sales will be calculated in the same
manner that Net Sales of GSK are calculated herein). Notwithstanding the
foregoing, if GSK or any of its Affiliates has used ALLERGAN's

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       6

<PAGE>

Confidential Information in connection with the commercialization of a Competing
Product as provided in this Section 4.4.2(a), ALLERGAN will have the right to
immediately terminate this Agreement and any other agreement between the Parties
relating to BOTOX in the Territory, upon thirty (30) calendar days' prior
written notice to GSK, which termination of this Agreement by ALLERGAN will be
deemed a termination by ALLERGAN pursuant to Section 6.3.1.

               (b) Notwithstanding anything contained in this Section 4.4.2,
nothing herein will, expressly or impliedly, preclude or restrict GSK, or any of
its Affiliates, in any way from (i) acquiring a majority of the voting stock, or
all or substantially all of the assets of, a Business Entity (as defined below);
(ii) being acquired by a Business Entity; or (iii) merging, amalgamating, taking
over, or consolidating (or engaging in any similar transaction) with a Business
Entity (hereinafter, the actions referred to in (i), (ii), and (iii) of this
Section 4.4.2(b) are collectively referred to as "MERGER" or "MERGING").

                    The term "BUSINESS ENTITY" as used in this Section 4.4.2(b)
means any Person, which, at the time of such Merger, is commercializing (as such
term is defined in Section 4.4.2(a)) a Competing Product in ***, including, for
example, the Persons listed on Exhibit D.

                    In the event that GSK or any of its Affiliates Merges with a
Business Entity during the Term, GSK will divest or cause the divestiture of the
Competing Product being commercialized by the Business Entity within *** after
the date of the public announcement of such Merger ("MERGER DATE"). During such
*** period, (A) neither GSK nor any of its Affiliates will use any ALLERGAN
Confidential Information in connection with the commercialization of such
Competing Product; and (B) GSK will continue to comply with the terms of this
Agreement in all respects. If GSK does not divest or cause the divesture of such
Competing Product within *** after the Merger Date, ALLERGAN, at any time
thereafter, will have a right to terminate this Agreement and any other
agreement between the Parties relating to BOTOX in the Territory, which
termination of this Agreement by ALLERGAN will be deemed a termination by
ALLERGAN pursuant to Section 6.3.1. In the event that GSK does not divest or
cause the divesture of such Competing Product within the *** period as provided
in this Section 4.4.2(b), GSK will pay to ALLERGAN *** of all of GSK's or its
successor's net sales of such Competing Product after such *** period (which net
sales will be calculated in the same manner that Net Sales are calculated
herein) and continuing until the earlier of the date on which GSK or its
successor divests such Competing Product or the expiration of the Restrictive
Period.

     4.5 Restrictive Covenant of ALLERGAN. In consideration for GSK's agreement
to the terms set forth in Section 4.4 above, ALLERGAN covenants to GSK as
follows:

          4.5.1 ALLERGAN will not, and will cause all of its Affiliates and
sublicensees not to, either on its or their own or with any Third Party, conduct
any development activities or conduct clinical trials relating to BOTOX, or seek
any regulatory approvals for BOTOX, in any country in Territory during the Term,
except as specifically permitted in any agreements between the Parties relating
to BOTOX in such countries; and

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       7

<PAGE>

          4.5.2 ALLERGAN will not, and will cause all of its Affiliates and
sublicensees not to, either on its or their own or with any Third Party, use,
sell, offer for sale or import BOTOX in any country in the Territory during the
Term, except, as specifically permitted in any agreements between the Parties
relating to BOTOX in such countries or as otherwise authorized by GSK in
writing.

5.   INDEMNIFICATION AND INSURANCE

     5.1 Indemnification by ALLERGAN. ALLERGAN will indemnify, defend, and hold
GSK and its Affiliates and their directors, officers, employees, and agents
(each and collectively a "GSK INDEMNITEE") harmless from and against any and all
liabilities, damages, losses, costs and expenses, investigations, and reasonable
attorneys' fees incurred hereunder (each and collectively a "LIABILITY")
resulting from or arising out of a claim, suit, or proceeding brought by a Third
Party against a GSK Indemnitee arising out of or related to: (a) any violation
of Applicable Law by any ALLERGAN Indemnitee in performing ALLERGAN's
obligations under this Agreement and/or (b) any material breach by any ALLERGAN
Indemnitee of this Agreement; except as to each of (a) and (b), to the extent
that any such Liabilities are the responsibility of GSK pursuant to Section 5.2.

     5.2 Indemnification by GSK. GSK will indemnify, defend, and hold harmless
ALLERGAN and its directors, officers, employees, agents, and consultants (each
and collectively an "ALLERGAN INDEMNITEE") from and against any and all
Liabilities resulting from or arising out of a claim, suit, or proceeding
brought by a Third Party against an ALLERGAN Indemnitee arising out of or
related to: (a) any violation of Applicable Law by any GSK Indemnitee in
performing GSK's obligations under this Agreement and/or (b) any material breach
by any GSK Indemnitee of this Agreement; except as to each of (a) and (b) to the
extent such Liabilities are the responsibility of ALLERGAN pursuant to Section
5.1.

     5.3 Procedure. For purposes of Sections 5.1 and 5.2, the Person asserting a
claim for indemnification pursuant to either Section 5.1 or 5.2 (the
"INDEMNIFIED PERSON") will notify the Party responsible for such indemnification
(the "INDEMNIFYING PARTY") in writing of any claims, suits, or proceedings by
Third Parties that may give rise to any claim for which indemnification may be
required under this Article 5 as follows: (a) within fifteen (15) calendar days
after receipt of service of process of the commencement of suit or (b) for
non-litigated matters, within thirty (30) calendar days after receipt of notice
thereof; provided, however, that failure to give such notice will not relieve
the Indemnifying Party of its obligation to provide indemnification hereunder
except if, and to the extent that, such failure materially and adversely affects
the ability of the Indemnifying Party to defend the applicable claim, suit, or
proceeding. The Indemnifying Party will be entitled to assume sole control over
the defense of any such claim at its own cost and expense; provided, however,
that the Indemnified Person will have the right to be represented by its own
counsel at its own cost in such matters. Neither the Indemnifying Party nor the
Indemnified Person will settle or dispose of any such matter in any manner that
would adversely affect the rights or interests of the other, require the other
to be subject to an injunction, or require the other to make any monetary
payment, in each case without the prior written consent of the other, which will
not be unreasonably withheld or delayed. The Indemnifying Party and

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                        8

<PAGE>

Indemnified Person will reasonably cooperate with the other and its counsel in
the course of the defense of any such suit, claim, or demand, such cooperation
to include without limitation using reasonable efforts to provide or make
available documents, information, and witnesses.

     5.4 Limitation of Liability. With respect to any claim by one Party against
the other arising out of the performance or failure of performance of the other
Party under this Agreement, the Parties expressly agree that the liability of
such Party to the other Party for such breach will be limited under this
Agreement or otherwise at law or equity to direct damages only and in no event
will a Party be liable for indirect, special, punitive, exemplary, or
consequential damages. The limitations set forth in this Section 5.4 will not
apply with respect to the obligations of either Party to indemnify the other
under Sections 5.1 or 5.2 in connection with a claim of a Third Party.

     5.5 Insurance. Each Party, at its own expense, will maintain commercial
general (public liability)/ product liability insurance, including coverage for
clinical trials, with a minimum limit of liability per occurrence of, or the
equivalent of, *** and *** in the annual aggregate, or self insure for any such
amounts, and will provide the other Party with a certificate of such insurance.
Each Party will provide at least thirty (30) calendar days' written notice to
the other Party prior to cancellation or material change in the relevant Party's
policy or coverage.

6.   TERM AND TERMINATION

     6.1 Term. The term of this Agreement will commence upon the Effective Date
and shall continue until December 31, 2009, unless extended by the mutual
agreement of the Parties or earlier terminated pursuant to Section 6.2 (the
"TERM").

     6.2 Extension of the Term. If GSK desires some or all of the Support
Services to continue beyond December 31, 2009, then prior to the expiration of
the Term as provided in Section 6.1 above, GSK will send written notice to
ALLERGAN of its desire to extend the Term, and the Parties will negotiate in
good faith an extension of the Term and the new terms for such extended Term, if
any.

     6.3 Early Termination.

          6.3.1 Termination Due to Breach. In the event of a material breach or
default of this Agreement by either Party that is not cured within *** after
receipt of notice thereof from the other Party, the non-breaching Party will be
entitled to terminate this Agreement by giving written notice to the other
Party, such termination to take effect immediately. The right to terminate this
Agreement will not be affected in any way by a waiver of, or failure to take
action with respect to, any previous default.

          6.3.2 Termination for Bankruptcy. Either Party will have the right to
terminate this Agreement effective upon written notice to the other Party in the
event the non-notifying Party becomes insolvent or makes an assignment for the
benefit of creditors, or in the event bankruptcy

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                        9

<PAGE>

or insolvency proceedings are instituted against the non-notifying Party or on
the non-notifying Party's behalf.

          6.3.3 Termination of Activities Relating to BOTOX. Either Party will
have the right to terminate this Agreement effective upon written notice to the
other Party in the event that GSK or its Affiliate is not developing or
commercializing BOTOX in the Territory.

     6.4 Effect of Expiration or Termination. Upon termination or expiration of
this Agreement, (i) ALLERGAN will cease providing the Support Services, (ii)
each Party shall promptly return to the other all Confidential Information of
the other Party received under this Agreement then in its possession or in the
possession of its Affiliates; provided that each Party may, at such Party's
expense, make and retain one (1) copy of the other Party's Confidential
Information for legal archival purposes only, and (iii) except for any payment
hereunder that accrued prior to the effective date of such expiration or
termination, but has not been paid, neither Party will have any further rights
or obligations under this Agreement.

     6.5 Survival. Termination or expiration of this Agreement for any reason
will terminate all outstanding obligations and liabilities between the Parties
arising from this Agreement except those described in:

          6.5.1 Sections 3.2, 3.4.1, 6.4, 6.5, 6.6, 8.4, 8.6, 8.7, 8.9, 8.10,
and 8.11, and Articles 5 and 7, all of which will survive termination or
expiration of this Agreement for the time period specified in such Sections and
Articles; provided, however, that if no such time period is specified in such
Sections and Articles, they will all survive termination or expiration of this
Agreement indefinitely; and

          6.5.2 Article I for the sole purposes of interpreting the obligations
and liabilities between the Parties surviving termination of this Agreement.

     6.6 No Waiver of Remedies. Termination of this Agreement will not preclude
either Party from (a) claiming any other damages, compensation or relief that it
may be entitled to upon such termination, (b) any right to receive any amounts
accrued under this Agreement prior to the termination date but which are unpaid
or become payable thereafter and (c) any right to obtain performance of any
obligation provided for in this Agreement which shall survive termination.

7.   CONFIDENTIALITY

     7.1 Confidential Information. "CONFIDENTIAL INFORMATION" means, except as
provided below in this Section 7.1, the terms and conditions of this Agreement
as well as confidential and proprietary information of a Party, whether in
written, printed, verbal, or electronic form, and whether disclosed before or
after the Effective Date, including research and development activities, BOTOX
design details and specifications, technology and know-how, sales and marketing
plans, finances and business forecasts, procurement requirements and vendor
information, customer lists, personnel information and strategic plans.
Confidential Information will not include information that: (a) is now, or
hereafter becomes, generally known or available

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       10

<PAGE>

to the public through no act or failure to act on the part of the receiving
Party; (b) was acquired by the receiving Party before receiving such information
from the disclosing Party through no breach of any duty of confidentiality owed
to the disclosing Party and without restriction as to use or disclosure; (c) is
hereafter rightfully furnished to the receiving Party by a Third Party without
any breach of any duty of confidentiality owed to the disclosing Party and
without restriction as to use or disclosure; or (d) is information that the
receiving Party can document was independently developed by the receiving Party
without any use of the disclosing Party's Confidential Information.

     7.2 Non-Disclosure of Confidential Information. Each Party, when it is the
receiving Party, agrees: (a) to hold the disclosing Party's Confidential
Information in strict confidence and not to disclose such Confidential
Information to any other Third Party without the prior written consent of the
disclosing Party; (b) not to use, at any time following the Effective Date, any
Confidential Information of the disclosing Party for its own benefit or for the
benefit of any Third Party for any purpose other than for the express purposes
permitted under this Agreement or any other agreement between the Parties
relating to BOTOX; and (c) to limit the disclosure of Confidential Information
to Permitted Persons. For purposes hereof, the term "PERMITTED PERSON" will mean
the receiving officers and employees of the receiving Party or of an Affiliate
of the receiving Party who have a need to know in order to carry out the
obligations under this Agreement or any other agreement between the Parties
relating to BOTOX; provided each has agreed in writing to maintain the
confidentiality of the Confidential Information in a manner no less protective
than that set forth herein or in any other agreement between the Parties
relating to BOTOX. The receiving Party will use Confidential Information of a
disclosing Party solely to exercise its rights and perform its obligations under
this Agreement or any other agreement between the Parties relating to BOTOX
(including without limitation the right to use and disclose such Confidential
Information in applications for regulatory approval and regulatory filings in
the Territory), unless otherwise mutually agreed in writing. The receiving Party
will take the same degree of care with Confidential Information of a disclosing
Party that it uses to protect its own confidential and proprietary information
of a similar nature and importance (but in any event no less than reasonable
care).

     7.3 Legal Disclosure. In the event a receiving Party is required to
disclose Confidential Information of the disclosing Party by any Applicable Law,
it may do so only to the extent required thereby; provided, however, that the
receiving Party will (a) use reasonable efforts under the circumstances to
provide advance notice to the disclosing Party of the required disclosure to
allow the disclosing Party an opportunity to take steps to object to, prevent,
or limit its disclosure or obtain a protective or other similar order with
respect to the required disclosure and (b) restrict disclosure to only that
portion of the Confidential Information that is required to be disclosed.
Remedies. The receiving Party agrees that its obligations hereunder are
necessary and reasonable to protect the disclosing Party's business interests
and that the unauthorized disclosure or use of Confidential Information of a
disclosing Party would cause irreparable harm and significant injury, the degree
of which may be difficult to ascertain. The receiving Party further acknowledges
and agrees that in the event of any actual or threatened breach of this
Agreement, the disclosing Party may have no adequate remedy at law and,
accordingly, that the disclosing Party will have the right to seek an immediate
injunction enjoining any breach or threatened breach of this Agreement, as

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       11

<PAGE>

well as the right to pursue any and all other rights and remedies available at
law or in equity for such breach or threatened breach.

     7.4 Return of Confidential Information. Upon the request of the disclosing
Party, the receiving Party will promptly return to the disclosing Party or, upon
the disclosing Party's written approval, destroy all material embodying
Confidential Information of the disclosing Party in its possession or under its
control, including all copies thereof; provided that each Party may, at such
Party's expense, make and retain one (1) copy of the other Party's Confidential
Information for legal archival purposes only.

     7.5 Disclosure of Agreement, Publicity, and Publications. Except as
expressly provided otherwise in Section 7.3, neither GSK nor ALLERGAN will
release to any Third Party or publish in any way any non-public information with
regard to the terms of this Agreement or concerning their cooperation without
the prior written consent of the other, which consent will not be unreasonably
withheld or delayed. Nothing in the foregoing, however, will prohibit a Party
from making disclosures to the extent deemed necessary under applicable federal
or state securities laws or any rule or regulation of any nationally recognized
securities exchange. In such event, however, the disclosing Party will use good
faith efforts to consult with the non-disclosing Party prior to such disclosure
and will request confidential treatment to the extent available. Subject to the
foregoing, ALLERGAN will issue a press release, public statement, or disclosure
regarding this Agreement, which press release, public statement or disclosure
will be mutually agreed upon by the Parties. ALLERGAN acknowledges and agrees
that GSK may publish the results of clinical trials conducted by GSK with the
BOTOX after the Effective Date on GSK's Clinical Trial Register and that such
publication will not be a breach of the confidentiality obligations provided in
Section 7.2. ALLERGAN agrees to cooperate with GSK in such effort, including
using commercially reasonable efforts to provide GSK with the protocols,
results, data, and other information relating to all clinical trials conducted
by GSK with BOTOX in ALLERGAN's possession that GSK reasonably requires to be
published on GSK's Clinical Trial Register.

     7.6 ALLERGAN Data Protections. GSK agrees and understands that ALLERGAN
Confidential Information, including but not limited to data, disclosed to GSK is
very sensitive and ALLERGAN would not enter into this Agreement without
additional assurances from GSK with respect to GSK's use of such Confidential
Information of ALLERGAN or possible disclosure of such Confidential Information
to ALLERGAN's competitors. Accordingly GSK will not use any such Confidential
Information in connection with any botulinum toxin research and/or development
other than as provided under this Agreement or as provided in any other
agreement between the Parties relating to BOTOX.

     7.7. Termination. All obligations of confidentiality and non-use imposed
under this Article 7 will expire *** after the date of expiration or termination
of this Agreement, except that Article 7 obligations of confidentiality and
non-use will continue thereafter with respect to manufacturing and regulatory
information, including without limitation filings with regulatory bodies.

8.   GENERAL PROVISIONS

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       12

<PAGE>

     8.1 Integration/Modification. This Agreement by and between the Parties
hereto, is both a final expression of the Parties' agreement and a complete and
exclusive statement with respect to all of its terms. The exhibits referred to
in this Agreement are incorporated herein and made a part of this Agreement by
this reference. This Agreement supersedes all prior and contemporaneous
agreements and communications, whether oral, written or otherwise, concerning
any and all matters contained herein; provided, however, that the
confidentiality provisions of Article 7 are in addition to and do not supersede
the terms and conditions of the Confidential Disclosure Agreement between
Allergan Inc. and GlaxoSmithKline Research & Development Limited, an Affiliate
of GSK, dated October 6, 2004, and any amendments thereto. No rights or licenses
are granted or deemed granted hereunder or in connection herewith, other than
those rights expressly granted in this Agreement. No trade customs, courses of
dealing, or courses of performance by the Parties will be relevant to modify,
supplement, or explain any term used in this Agreement. This Agreement may only
be modified, altered, amended, or supplemented in a writing expressly stated for
such purpose and signed by the Parties to this Agreement.

     8.2 Relationship Between the Parties. The Parties have no ownership
interest in the other and their relationship, as established by this Agreement,
is solely that of independent contractors. This Agreement does not create any
partnership, joint venture, or similar business relationship between the
Parties. Neither Party is a legal representative of the other Party, and neither
Party can assume or create any obligation, representation, warranty, or
guarantee, express or implied, on behalf of the other Party for any purpose
whatsoever.

     8.3. Non-Waiver. The failure of a Party to exercise, enforce, or insist
upon strict performance of any provisions of this Agreement, or rights of or
arising out of this Agreement, will neither impair that provision or right nor
constitute a waiver of that provision or right, in whole or in part, and will
not be construed to be a waiver of such rights or provisions, or a waiver by
such Party to thereafter enforce such rights or provision or any other rights or
provisions hereunder. No waiver will be effective unless made in writing and
signed by the waiving Party.

     8.4 Assignment. This Agreement is binding upon and inures to the benefit of
the Parties, and to their permitted successors and assigns. No Party may assign
or delegate any or all of its rights or obligations under this Agreement without
the prior written consent of the other Party except to an Affiliate. Any
assignment or delegation, or any other transfer or change of control by sale,
acquisition, merger, or otherwise, or attempt at the same, other than to an
Affiliate, made in the absence of such prior written consent will be void and
without effect; provided, however, that in the event of the foregoing, such
written consent will not be unreasonably withheld. If a Party assigns this
Agreement to an Affiliate, such Party will also promptly inform the other Party
and guarantee the performance by its Affiliate of all of such Party's
obligations under this Agreement. Either Party may, however, with notice, but
without consent and at its sole discretion, assign all of the rights and
obligations under this Agreement (excluding however, with regard to ALLERGAN,
any of its rights under Section 4.4) to a Third Party in connection the transfer
or sale of all or substantially all of its business, or in the event of its
merger or consolidation or change in control or similar transaction.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       13

<PAGE>

     8.5 No Third Party Beneficiaries. This Agreement is neither expressly nor
impliedly made for the benefit of any Person other than those executing it.

     8.6 Severability. If, for any reason, any part of this Agreement is
adjudicated invalid, unenforceable, or illegal by a regulatory authority or
court of competent jurisdiction, such adjudication will not affect or impair, in
whole or in part, the validity, enforceability, or legality of any remaining
portions of this Agreement. All remaining portions will remain in full force and
effect as if the original Agreement had been executed without the invalidated,
unenforceable, or illegal part.

     8.7 Notices. Any notice to be given under this Agreement must be in writing
and delivered either in person, by any method of mail (postage prepaid)
requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its address
given below, or at any address such Party has previously designated by prior
written notice to the other. Notice will be deemed sufficiently given for all
purposes upon the earlier of: (a) the date of actual receipt; (b) if mailed,
three (3) calendar days after the date of postmark; or (c) if delivered by
overnight courier, the next business day the overnight courier regularly makes
deliveries.

          If to GSK:

               Glaxo Group Limited
               Glaxo Wellcome House, Berkeley Avenue,
               Greenford, Middlesex, UB6 0NN, England
               Attention: Company Secretary
               Telephone:
               Facsimile:

          With a copy to:

               Smith Kline Beecham Corporation d/b/a GlaxoSmithKline
               2301 Renaissance Boulevard
               King of Prussia, PA 19406-2772
               Attention: Vice President and Associate General Counsel,
                          R&D Legal Operations, Business Development
                          Transactions Team
               Facsimile: 610-787-7084

          If to ALLERGAN:

               Allergan, Inc.
               2525 Dupont Drive
               Irvine, California 92612 U.S.A.
               Attention: General Counsel
               Telephone: (714) 246-4658
               Facsimile: (714) 246-6987

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       14

<PAGE>

               Allergan Sales, LLC
               2525 Dupont Drive
               Irvine, California 92612 U.S.A.
               Attention: Vice President, Operations
               Telephone: (714) 246-4767
               Facsimile: (714) 246-6557

     8.8 Force Majeure. Without prejudice to any rights of GSK set out in the
Supply Agreement, each Party will be excused from liability for the failure or
delay in performance of any obligation under this Agreement by reason of any
event beyond such Party's reasonable control, which materially impacts the
performance of the relevant Party's obligations under this Agreement including
but not limited to acts of God, fire, flood, earthquake, or other natural
forces, war, terrorism, civil unrest, or any other event similar to those
enumerated above (a "FORCE MAJEURE EVENT"). Such excuse from liability will be
effective only to the extent and duration of the Force Majeure Event(s) causing
the failure or delay in performance and provided that the Party has not caused
such Force Majeure Event(s) to occur. Notice of a Party's failure or delay in
performance due to a Force Majeure Event must be given to the other Party within
*** after its occurrence. All performance timelines under this Agreement that
have been affected by a Force Majeure Event will be suspended for the duration
of such Force Majeure Event.

     8.9 Disputes. If a dispute or controversy regarding any matter under this
Agreement, arises between the Parties which they are unable to resolve (a
"DISPUTE"), each of the Parties will (subject to any cure period as set forth in
this Agreement), be entitled to submit to the other Party written notice of such
Dispute, with such notice setting forth in reasonable detail the nature of the
Dispute (the "DISPUTE NOTICE"). For a period of thirty (30) calendar days after
the date of the receiving Party's receipt of the Dispute Notice, the Parties
will seek to resolve such Dispute by good faith negotiation between the
designated senior executives of the Parties. If at the end of such thirty (30)
calendar day period the Dispute remains unresolved, the Parties may seek relief
for such Dispute using any appropriate administrative or judicial mechanism
which may be available, subject to Section 8.11. The provisions of this Section
8.9 will not restrict in any way the Parties' rights to seek preliminary
injunctive or other equitable relief from any court having jurisdiction.

     8.10 Legal Fees. If any Party to this Agreement resorts to any legal action
in connection with this Agreement, the prevailing Party will be entitled to
recover reasonable fees of attorneys and other professionals in addition to all
court costs which that Party may incur as a result.

     8.11 Governing Law. Notwithstanding its place of execution or performance,
this Agreement, and all claims arising out of or relating to this Agreement,
will be governed by and construed in accordance with the laws of the State of
New York, irrespective of its laws regarding choice or conflict of laws. The
Parties hereby agree that for the purposes of resolving any Disputes hereunder,
in accordance with Section 8.9, that the Parties hereby submit to the exclusive
jurisdiction of the courts of New York.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       15

<PAGE>

     8.12 Interpretation.

          (a) Captions & Headings. The captions and headings of clauses
contained in this Agreement preceding the text of the articles, sections,
subsections and paragraphs hereof are inserted solely for convenience and ease
of reference only and will not constitute any part of this Agreement, or have
any effect on its interpretation or construction.

          (b) Singular & Plural. All references in this Agreement to the
singular will include the plural where applicable, and all references to gender
will include both genders and the neuter.

          (c) Articles, Sections & Subsections. Unless otherwise specified,
references in this Agreement to any article will include all sections,
subsections, and paragraphs in such article; references in this Agreement to any
section will include all subsections and paragraphs in such sections; and
references in this Agreement to any subsection will include all paragraphs in
such subsection.

          (d) Days. All references to days in this Agreement will mean calendar
days, unless otherwise specified.

          (e) Ambiguities. Ambiguities and uncertainties in this Agreement, if
any, will not be interpreted against either Party, irrespective of which Party
may be deemed to have caused the ambiguity or uncertainty to exist.

     8.13 Counterparts. This Agreement may be executed in one or more
counterparts (which may be delivered by facsimile), each of which will be deemed
an original document, and all of which, together with this writing, will be
deemed one instrument.

     8.14 Further Assurances. Each Party to this Agreement shall, at its own
expense, furnish, execute, and deliver all documents and take all actions as may
reasonably be required to effect the terms and purposes of this Agreement.

     8.15 Performance by Affiliates. The Parties recognize that each Party may
perform some or all of its obligations under this Agreement through Affiliates,
provided, however, that each Party will remain responsible for the performance
by its Affiliates and will cause its Affiliates to comply with the provisions of
this Agreement in connection with such performance. Each Party hereby expressly
waives any requirement that the other Party exhaust any right, power or remedy,
or proceed against an Affiliate, for any obligation or performance hereunder
prior to proceeding directly against such Party

     8.16 Compliance With Laws. Each Party will at all times comply with all
applicable laws and regulations relating to its activities under this Agreement.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       16

<PAGE>

     IN WITNESS WHEREOF, the Parties, intending to be bound hereby, have
executed this Agreement by their duly authorized representatives as of the date
first above written.

ALLERGAN, INC.                         GLAXO GROUP LIMITED

By: /s/ DAVID PYOTT                    By: /s/ LORRAINE DAY
    ---------------------------------      ------------------------------------
Name: David Pyott                      Name: Lorraine Day
      -------------------------------        ----------------------------------
                                             For and on behalf of
                                             Edinburgh Pharmaceutical Industries
                                             Limited

Title: Chairman and Chief Executive    Title: Corporate Director
       Officer                                ---------------------------------
       ------------------------------

ALLERGAN SALES, LLC

By: /s/ JEFFREY L. EDWARDS
    ---------------------------------
Name: Jeffrey L. Edwards
      -------------------------------
Title: Vice President and
       Chief Financial Officer
       ------------------------------

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       17

<PAGE>

                                    EXHIBIT A

                                  DELIVERABLES

Global Synergy Conference Calls - Semi-annual conference calls will be conducted
regarding BOTOX with ALLERGAN's (or its Affiliate's) lead contact and GSK's (or
its Affiliate's) lead contact, and such other individuals that such lead
contacts may want to include in such discussions, to share best practices,
update teams on key congress activities and publications, and gain shared
insight on competitive activities. In addition, such lead contacts or their
designees may also participate in additional conference calls or such other
means of communication, as agreed to by the Parties, as required from time to
time during Term, including, without limitation to coordinate activities
relating to Global Marketing's annual worldwide strategy development meeting
(described below), the Regional Tactical Plan (described below), and the
Semi-Annual Regional Interface.

Global and Territorial Situational Analysis - An annual BOTOX(R) worldwide and
Territory situational analysis including key development and competitive
assumptions, assessments of BOTOX strengths, BOTOX weaknesses, market
opportunities, and threats, and a compilation of critical market research
findings, all of which information will be set forth in a sufficiently detailed
written report, which will be generated in each Calendar Year for use in
developing global and Territory strategies. ALLERGAN will discuss the scope of
such situational analysis with GSK or its Affiliate prior to compiling the
information referred to herein to ensure that it will be acceptable to GSK (or
its Affiliate).

Strategy Development - GSK will be included in Global Marketing's annual
worldwide strategy development meeting, from which the key annual strategies
will be the output.

Regional Tactical Plan Consultation - During July through August, Global
Marketing will meet with GSK (but not for more than five (5) days during this
period) to assist in developing the local tactical plans and brand awareness
strategy for the Territory for the forthcoming year.

Semi-Annual Regional Interface - Global Marketing will conduct semi-annual
regional interface meetings through the end of 2009 with GSK's key marketing and
sales executives to assure that rapid attainment of expertise in marketing and
selling BOTOX(R) is achieved by GSK. It is intended that these meetings will be
one-day meetings but may be extended with the agreement of the parties in the
event of significant changes in the competitive landscape or prior to the launch
of new indications.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT B

                                PAYMENT SCHEDULE

                                 (U.S. Dollars)

The following payments will be made in accordance with Article 3:

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT C

                                WIRE INSTRUCTIONS

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT D

                              ALLERGAN COMPETITORS

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.<PAGE>
                                                                   Exhibit 10.55

                         CHINA BOTOX(R) SUPPLY AGREEMENT

                                 BY AND BETWEEN

                               GLAXO GROUP LIMITED

                                       AND

                        ALLERGAN PHARMACEUTICALS IRELAND

                               SEPTEMBER 30, 2005

<PAGE>

                         CHINA BOTOX(R) SUPPLY AGREEMENT

     THIS CHINA BOTOX(R) SUPPLY AGREEMENT (this "SUPPLY AGREEMENT") is made and
entered into effective as of September 30, 2005 (the "EFFECTIVE DATE"), by and
between ALLERGAN PHARMACEUTICALS IRELAND, a Cayman Islands corporation, having
its principal place of business at Carrowberg, Castlebar Road, Westport, County
Mayo, Ireland ("ALLERGAN") and GLAXO GROUP LIMITED, a company incorporated in
England, having its principal place of business at Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England ("GSK"). ALLERGAN and
GSK are hereinafter collectively referred to as the "parties" or individually as
a "party."

                                    RECITALS

     WHEREAS, Allergan, Inc. and Allergan Sales, LLC, Affiliates of ALLERGAN,
and GSK have entered into a separate License Agreement of even date herewith
pursuant to which GSK and its Affiliates have received, among other things, a
license to import, develop, promote, sell and distribute BOTOX(R) in the
People's Republic of China; and

     WHEREAS, Allergan, Inc. and Allergan Sales, LLC agreed in the License
Agreement to procure from ALLERGAN the supply of BOTOX(R)to GSK and its
Affiliates; and

     WHEREAS, GSK desires to purchase and ALLERGAN desires to sell to GSK all of
GSK's requirements of BOTOX(R), subject to the terms and conditions set forth
herein.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the parties agree as follows:

1.   DEFINITIONS

     1.1 Active Pharmaceutical Ingredient (API). "Active Pharmaceutical
Ingredient" or "API" means Botulinum Toxin Type A Manufactured by ALLERGAN to
the registered specifications at the API Manufacturing Facilities which is
intended to cause pharmacological activity or other direct effect in the
diagnosis, cure, treatment or prevention of disease or to affect the structure
or function of the body of human or animal.

     1.2 Affiliate. An "Affiliate" of a person or entity means any individual,
sole proprietorship, firm, partnership, corporation, trust, joint venture or
other entity, whether de jure or de facto, which, directly or indirectly,
controls, is controlled by or is under common control with such person or
entity. As used in this definition, "control" means the possession, directly or
indirectly, of the power to direct or cause the direction of the policies and
management of a person or entity, whether by the ownership of stock, by contract
or otherwise.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       1

<PAGE>

     1.3 Certificate of Analysis and Compliance. "Certificate of Analysis and
Compliance" means a document in the form set forth in Exhibit A (as may be
changed from time to time with the mutual agreement of the Parties), signed by
ALLERGAN's designated quality manager and provided by ALLERGAN to GSK, that sets
forth the analytical test results against the Specifications for a specified Lot
of Product and that certifies that each batch or Lot of Product was produced and
tested in compliance with the Specifications, cGMPs, the master batch record and
all applicable Marketing Authorizations and Manufacturing Authorizations.

     1.4 Change Control. "Change Control" means the process by which changes may
be made to the Product, as set forth in Section 2.5.

     1.5 cGMPs. "cGMPs" means all applicable standards relating to manufacturing
practices for fine chemicals, intermediates, bulk products or finished
pharmaceutical products. For purposes of this Supply Agreement, cGMPs shall mean
(i) the principles detailed in the People's Republic of China SFDA Regulation
No. 9 issued by the SFDA on 18 June 1999, ICH Q7a, U.S. cGMP 21CFR Parts 210 &
211 and The Rules Governing Medicinal Products in the European Community, Volume
IV Good Manufacturing Practice for Medicinal Products as each may be amended
from time to time or (ii) legislation or regulations or guidance documents
(including but not limited to advisory opinions, compliance policy guides and
guidelines) promulgated by any Regulatory Authority having jurisdiction over the
Manufacture of the Products, subject to any arrangements, additions or
clarifications agreed to from time to time by the parties.

     1.6 For Cause. "For Cause" means (i) an express requirement by the
Regulatory Authority in the Territory to conduct a root cause investigation by
way of an audit or (ii) an adverse event or serious problem in the Territory
that requires a root cause investigation that cannot be finally resolved or
concluded solely by a review of documentation.

     1.7 License Agreement. "License Agreement" means the License Agreement for
the Product entered into by GSK and Allergan, Inc. and Allergan Sales, LLC,
relating to the grant of certain rights and licenses under certain intellectual
property for development and/or commercialization of Product in the Territory
entered into on or about the date hereof.

     1.8 Lot. "Lot" means each separate and distinct batch or lot of Product
processed under continuous and identical conditions and designated by a unique
batch or lot number and expiration date.

     1.9 Manufacture. "Manufacture" or "Manufacturing" means the planning,
purchasing, manufacture, processing, compounding, storage, filling, packaging,
waste disposal, labeling, leafleting, testing, sample retention, stability
testing, release and dispatch of Products and such activities as may be required
for ALLERGAN to manufacture and supply each Product respectively in accordance
with this Supply Agreement.

     1.10 Manufacturing Facility. "Manufacturing Facility" or "Manufacturing
Facilities" means ALLERGAN's Westport, Ireland, secondary manufacturing
facility, or such other facility or facilities used by ALLERGAN in the
Manufacture of the Product (including the Active Pharmaceutical Ingredient
facilities), as may be designated from time to time by ALLERGAN in

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       2

<PAGE>

accordance with the Change Control procedure. Throughout this Supply Agreement
the term Manufacturing Facilities means both the secondary manufacturing
facility at Westport and the API manufacturing facilities. Each type of facility
will be referred to separately, as necessary, as the "API Manufacturing
Facility" and the "Secondary Manufacturing Facility".

     1.11 Manufacturing Authorization. "Manufacturing Authorization" means, with
respect to the Territory, the regulatory authorization required to Manufacture
the Product and the API at the Manufacturing Facilities as granted by the
relevant Regulatory Authority in the Territory or the country of Manufacture, as
the case may be.

     1.12 Marketing Authorization. "Marketing Authorization" means the
approvals, licenses, registrations or authorizations (as may be amended or
updated from time to time) necessary for GSK to import and sell the Product in
the Territory.

     1.13 Materials. "Materials" means the raw materials (including API),
components and other ingredients required to Manufacture the Product, each as
specifically identified in the Marketing Authorization.

     1.14 Product. "Product" means finished drug product containing the API and
Manufactured by ALLERGAN to the Specifications for supply to GSK under the terms
of this Supply Agreement.

     1.15 Product Change. "Product Change" shall have the meaning set forth in
Section 2.4.

     1.16 Quality Obligations. "Quality Obligations" means the additional
quality obligations set out at Exhibit F.

     1.17 Regulatory Authority. "Regulatory Authority" means the national,
supranational, regional, state or local regulatory agency, department, bureau,
commission, council or other government entity involved in the granting of
Marketing Authorization for the Product in the Territory or Manufacturing
Authorization for the Product or API in the Territory or the country of
manufacture.

     1.18 Specifications. "Specifications" means the specifications for the
Product in finished pack form as approved by the Regulatory Authority in the
Territory and as set forth in the Marketing Authorization and the form of
Certificate of Analysis and Compliance.

     1.19 Standard Cost. "Standard Cost" means ALLERGAN's internal standard
cost, comprising direct and indirect fully allocated costs to Manufacture
Botulinum Toxin Type A at the Manufacturing Facility for supply to GSK or any of
ALLERGAN's other customers (be they Third Parties or Affiliates), including
without limitation the ***, determined in accordance with applicable law and
U.S. generally accepted accounting principles using methodology consistently
applied by ALLERGAN.

     1.20 Term. "Term" shall have the meaning set forth in Section 8.1.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       3

<PAGE>

     1.21 Territory. "Territory" means the People's Republic of China and its
territories and possessions, provided that the Territory shall not include
Taiwan, Hong Kong or Macau.

     1.22 Third Party. "Third Party" means any person or entity other than
ALLERGAN or GSK or either of their Affiliates.

     1.23 Unit. "Unit" shall mean each separate stock keeping unit of Product
with a distinct product number or item code.

     1.24 VAT & Indirect Taxes. "VAT & Indirect Taxes." means the tax imposed by
the sixth council directive of the European Community and any national
legislation implementing that directive together with legislation supplemental
thereto and in particular, in relation to the United Kingdom, the tax imposed by
the Value Added Tax Act of 1994 or other tax of a similar nature, including
sales taxes, imposed elsewhere instead of or in addition to value added tax.

2.   MANUFACTURE AND SUPPLY

     2.1 General. During the Term, and subject to the terms and conditions of
this Supply Agreement, GSK agrees to purchase all of its clinical trial and
commercial requirements of Product for the Territory exclusively from ALLERGAN,
and ALLERGAN agrees to sell to GSK and relevant GSK Affiliates all of GSK's
requirements of Product for the Territory. ALLERGAN shall be the exclusive
supplier of Product to GSK, its Affiliates and any permitted sublicensees or
assignees for the Territory.

     2.2 Manufacturing.

          (a) ALLERGAN shall only Manufacture the Product at the Secondary
Manufacturing Facilities and the API at the API Manufacturing Facilities. ***,
all Product shall be supplied to GSK from ALLERGAN's Secondary Manufacturing
Facility***. GSK acknowledges that ALLERGAN intends to add, within the next
three years, an additional production line at the Secondary Manufacturing
Facility at Westport, Ireland, ("CORE 3") and an additional API Manufacturing
Facility. If ALLERGAN wishes to change the facility at which ALLERGAN
Manufactures Product or API or add additional facilities at which ALLERGAN
Manufactures Product or API, ALLERGAN shall provide GSK with prior written
notice to that effect in order to allow GSK to comply with its regulatory and
legal obligations and obtain any necessary approvals from a Regulatory Authority
of amendments to Marketing Authorizations in relation to such a change. Any
changes to the Manufacturing Facilities that cause a Product Change will be
dealt with in accordance with the Change Control procedure set out in Section
2.5. Notwithstanding the foregoing, ALLERGAN shall supply GSK with Product
pursuant to Marketing Authorizations for the Territory, and ALLERGAN shall
maintain sufficient supplies of approved Product to supply GSK its requirements
for the Territory until approvals from a Regulatory Authority of amendments to
Marketing Authorization in the Territory is obtained for any changes to the
Manufacturing Facilities. ALLERGAN shall obtain any necessary Manufacturing
Authorizations from the Regulatory Authority in the country of Manufacture prior
to any modifications to the API Manufacturing Facilities or Secondary
Manufacturing Facilities.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       4

<PAGE>

ALLERGAN will be solely responsible for obtaining necessary Manufacturing
Authorizations in the country of Manufacture for Manufacturing the Product at
any Secondary Manufacturing Facility and the API at any API Manufacturing
Facility. GSK shall obtain (with reasonable assistance from ALLERGAN) any
necessary Marketing Authorizations from the Regulatory Authority in the
Territory prior to any modifications to the API Manufacturing Facilities or
Secondary Manufacturing Facilities. GSK shall be diligent in its efforts to
obtain approvals from a Regulatory Authority of amendments to Marketing
Authorizations in the Territory to any Product Changes, with the support of
ALLERGAN, in order to ensure that ALLERGAN may implement such Product Changes as
soon as possible. ALLERGAN shall be diligent in its efforts to obtain
Manufacturing Authorization in the country of Manufacture to any Product
Changes, with the support of GSK, in order to ensure that ALLERGAN may implement
such Product Changes as soon as possible.

          (b) ALLERGAN shall be solely responsible for ordering the relevant
quantities of Materials and for the timely delivery of such Materials. ALLERGAN
shall purchase and use only Materials in the Manufacture of the Product which
comply with the requirements of cGMP, the Manufacturing Authorizations and
Marketing Authorization, and which have been tested in accordance with the
Marketing Authorization and applicable law in the Territory. Any changes to the
suppliers of Materials that cause a Product Change will be dealt with in
accordance with the Change Control procedure set out in Section 2.5. ALLERGAN
shall at all times store and warehouse all Materials and Products Manufactured
by ALLERGAN pursuant to this Supply Agreement in premises that are secure and
clean.

          (c) ***

     2.3 Product Packaging & Labeling.

          (a) Each Unit of Product will be packaged and labeled by ALLERGAN with
Territory-specific language, indications, labeling and regulatory disclosures in
accordance with the Specifications, however, if the laws of the Territory
require some local packaging operations to be undertaken by GSK, the parties
will meet and discuss in good faith how to comply with such requirement. The
parties shall design the packaging and labeling, as set out in Section 2.3(b)
below, to the greatest extent possible, to prevent the Product from being
distributed and sold outside the Territory. Each Unit of Product shall bear a
label and be contained in an outer package and/or carton and, if applicable, be
accompanied by a package insert, which label, outer package and/or carton and/or
package insert shall comply with all applicable regulatory requirements in the
Territory and shall carry a legend clearly indicating that the Product was
licensed from ALLERGAN.

          (b) ALLERGAN and GSK shall jointly design and agree upon any changes
to the packaging and labeling for the Product sold in the Territory, and shall
use reasonable efforts to design such packaging and labeling to prevent the
Product manufactured for sale in the Territory from being distributed and sold
outside the Territory. If either party desires to change the packaging or
labeling for the Product, it shall submit the proposed change to the other party
for review and approval. The party receiving the proposed change shall promptly
review the proposal and respond in writing with its approval or disapproval
(together with its reasons for such

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       5

<PAGE>

disapproval). Any disputes regarding the design of labeling or packaging shall
be resolved in accordance with the dispute resolution procedures specified in
Section 10.9 of this Supply Agreement. GSK shall be responsible for ensuring
that the design of the packaging and labeling is compliant with applicable law
in the Territory. ALLERGAN's review and approval of the design of any packaging
or labeling shall not cause ALLERGAN to be liable or otherwise responsible for
the compliance of the design of the packaging and labeling with applicable laws,
provided that ALLERGAN shall not unreasonably withhold approval of any design or
proposal which is necessary (in GSK's opinion) for legal or regulatory
compliance purposes. For the avoidance of doubt, nothing in this Section 2.3(b)
shall limit or exclude ALLERGAN's liability attributable to the Manufacture of
the Product.

     2.4 Product Changes. All modifications to the Product (including changes to
Material suppliers), API, their Specifications or changes to the Manufacturing
process of the Product or API which may effect the legal or regulatory
obligations of GSK in the Territory (including the Marketing Authorizations) or
the Product's quality, efficacy or safety (together known as "PRODUCT CHANGE"),
shall be made in accordance with the Change Control procedure set out in Section
2.5 below. For the avoidance of doubt the Change Control Procedure, set out at
Section 2.5 below, shall not apply to modifications that do not effect the legal
or regulatory obligations of GSK in the Territory, or the Product's quality,
efficacy or safety.

     2.5 Change Control Procedure.

          (a) GSK shall provide ALLERGAN with written notice of any Product
Changes directed or recommended by the Regulatory Authority in the Territory as
soon as reasonably practicable and ALLERGAN shall promptly determine how best to
implement such Product Changes. If ALLERGAN determines that the Product Changes
directed or recommended by the Regulatory Authority in the Territory will
involve implementation costs of greater than ***, the parties will conduct good
faith negotiations to determine how best to implement the Product Changes.

          (b) ALLERGAN shall provide GSK with written notice of any proposed
Product Changes instigated by ALLERGAN at its discretion or by GSK in accordance
with Section 2.5(a) as soon as reasonably practicable.

          (c) GSK shall promptly review the proposal for Product Change and
respond in writing on whether the proposed Product Change requires any
notification to, or request for pre-approval from, the Regulatory Authority in
the Territory.

          (d) Where GSK determines that the proposed Product Change requires
notification or pre-approval from the Regulatory Authority in the Territory,
ALLERGAN will provide appropriate information to support GSK's submission to the
Regulatory Authority and shall maintain sufficient supplies of approved Product
to supply GSK its requirements for the Territory until approvals from a
Regulatory Authority of amendments to the Marketing Authorization in the
Territory is obtained for any Product Changes.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       6

<PAGE>

          (e) Any disagreement between the parties regarding Product Changes or
that arises during this Change Control procedure shall be discussed by the
party's relevant technical or operational representatives in good faith and in a
consultative manner and escalate the matter within their internal lines of
reporting as may be necessary. Where the parties are unable to resolve a
disagreement in relation to the legal obligations of either party it will be
resolved in accordance with the dispute resolution procedures set out in Section
10.9 of this Supply Agreement.

     2.6 Lead Contacts. Each party shall appoint a lead contact (who for
ALLERGAN shall be a senior manufacturing manager of ALLERGAN or Allergan, Inc.
and for GSK shall be a senior manufacturing manager of the Procurement &
Contract Manufacturing department of GSK's Global Manufacturing and Supply
Division) for the activities contemplated by this Supply Agreement. The lead
contact for each party shall be identified to the other party not later than ten
(10) days after the Effective Date. Either party may change its lead contact
upon written notice to the other party. In an endeavor to promote efficient and
effective sales and operations planning, the appropriate personnel from each
party shall meet in person or by telephone at mutually convenient times/places
on a regular basis to discuss, consider and, if seen fit, implement such sales
and operations planning measures as they consider appropriate to promote the
objects of this Supply Agreement. The Lead Contacts will also discuss, on a
regular basis, the strategies that ALLERGAN has in place to manage any risks
relating to interruption to supply.

3.   PRICE AND PAYMENT

     3.1 Purchase Price.

          3.1.1 Supply Price. For each Unit of Product supplied to GSK
hereunder, GSK shall pay ALLERGAN a price per Unit of Product equal to
ALLERGAN's Standard Cost per Unit in the Calendar Year in which the delivery
date specified by GSK occurs, as such Standard Cost is determined in accordance
with this Supply Agreement, plus *** (the "PRICE"). The Standard Cost as of the
Effective Date is *** per Unit, and the Price to be paid by GSK per Unit as of
the Effective Date is therefore ***. ALLERGAN may, though it shall not be
obliged to, use the assistance and expertise of GSK to identify and target
potential areas of reduction to its Standard Cost.

          3.1.2 Amendments to Supply Price. ALLERGAN shall recalculate the
Standard Cost once during the fourth quarter of each calendar year (either
upward or downwards as the case may be) (the "RECALCULATED STANDARD COST") to
become effective 1 January of the succeeding year. ALLERGAN shall provide GSK
with written notice detailing each Recalculated Standard Cost promptly after its
determination. Subject to the reconciliation process set out in Section 3.1.4
below, the Price paid by GSK from 1 January in each succeeding year during the
Term shall be the Recalculated Standard Cost for that year plus ***.

          3.1.3 Maximum Increase. For the purposes of the reconciliation process
set out in Section 3.1.4 below, (A) the maximum allowable increase to the
Standard Cost for calendar years through the end of *** shall be *** and (B) the
maximum allowable increase to the Standard Cost

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       7

<PAGE>

for calendar years from and after *** shall be *** (the "ALLOWABLE STANDARD
COST"). When calculating the Allowable Standard Cost for each Calendar Year
after the first Calendar Year, the 'Standard Cost' referred to in this Section
3.1.3 shall be the lower of Recalculated Standard Cost or the Allowable Standard
Cost for the immediately preceding Calendar Year.

          3.1.4 Reconciliation Process. In circumstances where the Recalculated
Standard Cost exceeds the Allowable Standard Cost, ALLERGAN will give a credit
to GSK to be used against the royalty payable under the License Agreement in an
amount equal to the difference between (A) the Recalculated Standard Cost plus
*** and (B) the Allowable Standard Costs plus ***, multiplied by the number of
Units purchased by GSK during the given year. A working example of this
reconciliation process is set forth in Exhibit G.

     3.2 Invoices. ALLERGAN shall invoice GSK or GSK's nominated Affiliate for
all Product purchased by GSK upon shipment in accordance with the delivery terms
and the requirements of Section 4.4 and such invoices shall be paid by GSK
within sixty (60) days of the date of the invoice. All amounts shall be invoiced
and paid in U.S. Dollars. Each invoice issued by ALLERGAN hereunder shall
specify: (a) the price in respect of the Product delivered; (b) the quantity of
the Product delivered; and (c) the amount of tax due in respect of the Product
delivered (if any).

     3.3 Taxes. All amounts in this Supply Agreement are stated exclusive of VAT
and Indirect Taxes. GSK is responsible for the payment of all such appropriately
levied taxes to ALLERGAN. ALLERGAN will provide to GSK within thirty (30) days
of the receipt of any consideration, valid VAT invoice if appropriate. Should
such amounts of VAT be refunded subsequently by the fiscal authorities to
ALLERGAN, ALLERGAN will refund these monies to GSK within thirty (30) days of
receipt.

     3.4 Wire Transfers. All payments hereunder shall be made to ALLERGAN by
bank wire transfer in immediately available funds to ALLERGAN in accordance with
the wire instructions set forth in Exhibit E, which may be changed only by
written notice to GSK from the Chief Financial Officer of ALLERGAN under Section
10.7 (Notices).

     3.5 Late Payments. Subject to the other terms of this Supply Agreement,
payments not made to ALLERGAN within the time period set forth in this Article 3
shall bear interest at an annual rate equal to *** per month. The payment of
such interest shall not limit ALLERGAN from exercising any other rights it may
have under this Supply Agreement as a consequence of the lateness of any
payment.

     3.6 Financial Audit Rights. ALLERGAN shall permit its independent
registered public accounting firm, who as of the Effective Date is Ernst & Young
LLP, acting for GSK, to have access, no more than once in each calendar year
during the term of this Supply Agreement, during regular business hours and upon
at least thirty (30) days' written notice, to ALLERGAN's records and books only
to the extent necessary to determine the accuracy of the Standard Cost or
Recalculated Standard Cost (as the case may be). Any report provided by
ALLERGAN's

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       8

<PAGE>

company appointed auditors to GSK shall, unless mutually agreed between the
parties, be limited to:

          (i)  a statement to verify that the Standard Cost is consistent or
               equivalent with ALLERGAN's internal standard cost; and

          (ii) in circumstances where the Standard Cost or Recalculated Standard
               Cost charged by ALLERGAN has been determined by the auditor to
               have been higher than ALLERGAN's internal standard cost ,
               disclosure of the actual standard cost.

     If such examination results in a determination that the Standard Cost or
Recalculated Standard Cost has been overstated, amounts overpaid by GSK shall be
refunded by ALLERGAN promptly. The fees and expenses of ALLERGAN's company
appointed auditors for conducting the services set out in this Section 3.6 shall
be paid by GSK unless the examination results in a determination that Standard
Cost or Recalculated Standard Cost have been overstated, or that amounts have
been overpaid by GSK, by more than *** for the period examined, in which case
ALLERGAN shall pay all reasonable costs and expenses of such auditor.

4.   FORECASTS, ORDERS AND SHIPMENT

     4.1 Rolling Forecasts. Prior to the beginning of each calendar quarter
during the Term, GSK shall provide ALLERGAN with a written forecast of GSK's
expected requirements for Product during the following eighteen (18) months
broken down by months (M1 through M18), and which shall include projected order
dates, quantities and shipping dates ("ROLLING FORECASTS"). The initial Rolling
Forecast shall be delivered to ALLERGAN by GSK within two (2) weeks after the
Effective Date. As pertains for each Rolling Forecast, the Units of Product set
forth in the first three (3) months designated M1-M3 shall be firm orders
binding on GSK, and the forecast for the second three (3) months designated
M4-M6 may only be increased or decreased by up to *** in the aggregate from the
original forecast for such months as the forecast is rolled forward at the
beginning of the next quarter (but in no event shall any order be for less than
*** Units), unless otherwise agreed to by ALLERGAN. Except as set forth in this
Section 4.1, the Rolling Forecasts shall be non-binding.

     4.2 Purchase Orders. Products shall be ordered by GSK by written or
electronic purchase order (or by any other means agreed to by the parties), the
initial form of which is attached as Exhibit B ("PURCHASE ORDER"). The initial
Purchase Order of Product by GSK to cover the balance of the calendar quarter in
which the Effective Date falls, which may account for a reasonable build of
stock for inventory purposes, shall be provided before or with the initial
Rolling Forecast. Prior to the beginning of each calendar quarter, but at least
thirty (30) days prior to the earliest desired date of delivery, GSK shall place
binding Purchase Orders for Product for M1-M3 as specified in the Rolling
Forecast to begin delivery in M1 of that calendar quarter, and shall be
consistent with the forecast provided for such calendar quarter in that Rolling
Forecast. Each Purchase Order must be for a minimum order of *** Units. Purchase
Orders placed by GSK may not be changed without ALLERGAN's prior written
consent. For the avoidance of doubt, the minimum order quantity for each
Purchase Order set out in this Section 4.2 does not represent a

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       9

<PAGE>

minimum annual volume commitment by GSK. To the extent of any conflict or
inconsistency between this Supply Agreement and any Purchase Order, purchase
order release, confirmation, acceptance or any similar document pertaining to
the supply of Product for sale in the Territory, the terms of this Supply
Agreement shall govern.

     4.3 Manufacture and Shipment. ALLERGAN shall deliver to GSK the number of
Units of Product specified in each Purchase Order no later than the dates
specified therein. ALLERGAN shall exercise the same diligence in meeting GSK's
requirements of Product as it exercises with respect to its own requirements.

     4.4 Delivery Terms. Shipments of Product to GSK shall be made FCA
Manufacturing Facility, Westport, Ireland, INCOTERMS 2000 (as defined by the
International Chamber of Commerce (ICC)). Delivery will not be complete unless
each shipment is accompanied by a valid Certificate of Analysis and Compliance
and any required export documentation.

     4.5 Manufacturing Capacity. ALLERGAN undertakes to ensure that it has at
all times sufficient Manufacturing capacity at the Manufacturing Facilities to
satisfy GSK's Product requirements set out in the Rolling Forecasts.

          (a) ALLERGAN shall routinely monitor the Manufacturing capacity
available to GSK at the Manufacturing Facilities, such that ALLERGAN shall make
appropriate changes to its utilization of such capacity to satisfy GSK's
requirements of Product in accordance with this Supply Agreement.

          (b) GSK and ALLERGAN shall review and discuss the Manufacturing
capacity available at the Manufacturing Facilities in relation to the Rolling
Forecast as part of the regular review meetings pursuant to Section 2.6.

          (c) In the event of a break or fault in production that can reasonably
be foreseen to affect supply of Product to GSK, ALLERGAN shall notify GSK
promptly if such fault cannot be remedied within five (5) business days and,
following such notification, will keep GSK apprised of the status of the
remedial action to be taken by ALLERGAN. ALLERGAN shall in any event use its
best endeavors to ensure a return to production as soon as possible.

     4.6 Minimum Inventory. During the Term, ALLERGAN shall maintain a
reasonable stock of inventory of Product and Materials throughout the supply
chain ("RESERVE SUPPLY"). The amounts of inventory specified in this Section
shall be based on the Rolling Forecast.

     4.7 Incomplete Delivery. GSK shall notify ALLERGAN as soon as reasonably
practicable, and in no event later than three (3) business days after receipt of
the delivery at GSK's site in the People's Republic of China, if there is an
incomplete delivery in accordance with the terms of this Supply Agreement. If
ALLERGAN is notified of the incomplete delivery by telephone or in person, then
such notification shall be confirmed by GSK in writing. ALLERGAN shall rectify
the incomplete delivery, making it up from the Reserve Supply if necessary,
within fourteen (14) business days after the first date of notification.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       10

<PAGE>

     4.8 Failure to Meet Requirements. If ALLERGAN is unable, or anticipates
that it will be unable, to supply at least *** of the Product ordered on any
Purchase Order placed in accordance with Section 4 from its current production
or normal stocks, ALLERGAN shall, promptly after it becomes aware of such fact,
and in any event not less than fourteen (14) days before the due delivery date,
give written notice to GSK of the reasons for the shortfall. ALLERGAN will make
up the shortfall in the next delivery of Product ordered by GSK. GSK's remedies
in the event of any failure of ALLERGAN to supply GSK's requirements under this
Supply Agreement are set forth in the License Agreement. GSK's SOLE AND
EXCLUSIVE REMEDIES FOR FAILURE OF SUPPLY SHALL BE LIMITED TO THE REMEDIES
PROVIDED IN THE LICENSE AGREEMENT.

5.   QUALITY AND SAFETY

     5.1 Compliance. ALLERGAN shall Manufacture and supply Product, and maintain
and operate the Manufacturing Facilities, in accordance with this Supply
Agreement, the Specifications, all applicable laws and regulations and the
applicable Marketing Authorizations, including any applicable cGMPs, Good
Quality Practices ("GQPS"), Good Vigilance Practices ("GVPS") provisions
promulgated by the Regulatory Authority in the Territory or the country of
Manufacture.

     5.2 Inspection by Regulatory Authorities. ALLERGAN shall permit
representatives of appropriate Regulatory Authorities from the Territory or
country of Manufacture to inspect the Manufacturing Facilities to verify the
Product and API is being manufactured and supplied in accordance with cGMPs,
GQPs, GVPs and Product Specifications, API specifications and in accordance with
the Manufacturing Authorizations and Marketing Authorizations. ALLERGAN shall
provide GSK with a copy of any report or deficiency notice arising from such
inspections conducted by Regulatory Authorities from the Territory or country of
Manufacture, appropriately redacted to maintain confidentiality of ALLERGAN's
proprietary trade secrets, however, for the avoidance of doubt, any major or
critical observations of the Regulatory Authority will be disclosed in
un-redacted form. GSK shall have the right to make recommendations to ALLERGAN
regarding corrective action provided that ALLERGAN shall make the final
determination with respect to the corrective action taken. ALLERGAN shall
promptly remedy or cause the remedy of any deficiencies which may be noted in
any such inspection by the Regulatory Authority.

     5.3 ***

     5.4 Inspections by GSK of the Secondary Manufacturing Facility. GSK may,
subject to Section 9 relating to Confidentiality, conduct routine inspections of
the Secondary Manufacturing Facility to verify the Product is being Manufactured
and supplied in accordance with cGMPs, GQPs, GVPs and Product Specifications and
in accordance with the Manufacturing Authorizations and Marketing
Authorizations. *** Plant inspections by GSK shall be conducted during normal
business hours on not less than thirty (30) days advance written notice, and
shall occur no more frequently than once in any twelve (12) consecutive month
period, provided that GSK shall have

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       11

<PAGE>

the right to carry out follow up inspections where it is legally obliged to do
so. GSK shall have the right to carry out inspections For Cause at any time. Any
For Cause inspection will be limited to an investigation of the For Cause issue
to discover the root cause. ALLERGAN and GSK shall meet after each inspection to
discuss the results of the inspection. ALLERGAN shall give due consideration to
observations and recommendations made by GSK at such meetings. Any Product
Changes as a result of the inspection shall be made in accordance with the
Change Control procedure set out in Section 2.5. Any disagreements between the
parties regarding the results of the inspection shall be discussed by the
party's relevant technical or operational representatives in good faith and in a
consultative manner and escalate the matter within their internal lines of
reporting as may be necessary. Where the parties are unable to resolve a
disagreement in relation to the legal obligations of either party it will be
resolved in accordance with the dispute resolution procedures set out in Section
10.9 of this Supply Agreement.

     5.5 Shelf Life. The shelf life of the Product is three (3) years. Product
shall have a minimum of *** of shelf life remaining at time of delivery to GSK.

     5.6 Specification Testing. ALLERGAN shall test or cause to be tested, in
accordance with the test methods and procedures set forth in Exhibit C, each Lot
sold to GSK before delivery to GSK. ALLERGAN shall provide GSK with a
Certificate of Analysis and Compliance, which shall accompany each Lot delivered
to GSK. In addition, GSK may test or cause to be tested each shipment of Product
received by GSK for the Territory. FOR THE AVOIDANCE OF DOUBT, EXCEPT AS SET OUT
IN SECTION 5.10, ANY TESTING BY GSK SHALL NOT SERVE TO LIMIT OR EXCLUDE
ALLERGAN'S LIABILITY OR RELIEVE ALLERGAN FROM ITS OBLIGATIONS SET OUT IN THIS
SUPPLY AGREEMENT.

     5.7 Replacement or Credit for Refund. If GSK rejects any Lot of Product,
GSK shall promptly notify ALLERGAN in writing of the reason(s) for rejection.
Following discussion with GSK and by mutual agreement ALLERGAN shall, either
promptly replace the entire Lot in which the defective Product was found and
deliver it to GSK at ALLERGAN's sole cost and expense or credit to GSK the
invoiced amount of the entire Lot in which the defective Product was found and
credit to GSK the actual cost of transportation and storage of the defective
Product incurred by GSK. After consultation with ALLERGAN, GSK may dispose of
any defective Lot in such reasonable manner as GSK determines in its sole
discretion at ALLERGAN's cost and expense. OTHER THAN THE REMEDIES FOR FAILURE
TO SUPPLY SET OUT IN THE LICENSE AGREEMENT, GSK's SOLE AND EXCLUSIVE REMEDY FOR
REJECTION OF ANY LOT OR ANY UNITS OF ANY LOT SHALL BE LIMITED TO THE REMEDY
PROVIDED IN THIS SECTION.

     5.8 Disputes Regarding Defect Claims. In the event of a dispute between the
parties over the validity of a rejection of a Lot of Product, GSK and ALLERGAN
agree to submit samples of the rejected Product to an independent test facility
to be agreed upon by both parties, and to accept the results of the testing
performed by that facility as binding with regard to that Lot. The expense of
such testing shall be borne by the losing party. The parties acknowledge that
the time period for accurate testing for the Product could impact the flow of
Product to market and that it may be necessary to send a replacement Lot of
Product (which ALLERGAN shall invoice GSK

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       12

<PAGE>

for in the normal course of business) pending determination or resolution of the
validity of a rejection.

     5.9 Adverse Event (AE) and Serious Adverse Event (SAE) Reporting. GSK and
ALLERGAN shall each comply with their obligations in relation to medical event
reporting requirements as set out in the License Agreement.

     5.10 Product Recall. If any Regulatory Authority in the Territory orders or
requires the recall of any Product in the Territory, or if in GSK's opinion a
recall is necessary in the Territory, GSK will promptly notify ALLERGAN and
provide such information regarding such recall order or other information as may
be reasonably requested by ALLERGAN. GSK shall, unless prohibited by applicable
law, consult with ALLERGAN on the need for a recall and take all ALLERGAN
submissions into account when making a decision whether to instigate a recall
(such decision not to be unreasonably made). GSK shall be responsible for
conducting any recall of Product in the Territory and ALLERGAN shall co-operate
with GSK by providing all such information and assistance as may be reasonably
required to implement such recall. To the extent that any recall of the Product
is implemented as a result of ALLERGAN's failure to Manufacture Product in
accordance with the terms and conditions of this Supply Agreement, ALLERGAN
shall (i) bear all direct expenses incurred by GSK in connection with such
recall, (ii) shall indemnify the GSK Indemnitees (as defined in Section 7.1)
from any and all Liabilities (as defined in Section 7.1) incurred by any GSK
Indemnitee, to the extent that these are proven to be attributable to ALLERGAN's
failure to Manufacture Product in accordance with the terms and conditions of
this Supply Agreement and (iii) shall either, at GSK's sole option, replace or
credit GSK for the cost of the relevant Lots of the Product subject to the
recall. If a recall of Product is required due to any negligence or willful
misconduct of a GSK Indemnitee, including without limitation any recall that
could have been avoided but was not avoided due to a failure of GSK to perform
the testing allowed by Section 5.6, GSK shall bear all such costs and expenses
incurred in connection with such recall and shall indemnify the ALLERGAN
Indemnitees from and against any and all Liabilities incurred by an ALLERGAN
Indemnitee that are proven to be attributable solely to the negligence or
willful misconduct of GSK. If any Regulatory Authority outside the Territory
orders or requires the recall of any of the Products outside the Territory then
ALLERGAN will promptly notify GSK and provide such information regarding such
recall order or other information as may be reasonably requested by GSK. EXCEPT
AS SET FORTH IN ARTICLE 7 (INDEMNIFICATION), EACH PARTY'S SOLE AND EXCLUSIVE
REMEDIES FOR RECALLED PRODUCT SHALL BE LIMITED TO THE REMEDIES PROVIDED IN THIS
SECTION AND, IF RELEVANT, THE REMEDIES FOR FAILURE TO SUPPLY SET OUT IN THE
LICENSE AGREEMENT.

     5.11 Quality Obligations. Exhibit F sets forth additional provisions
governing the Manufacture by ALLERGAN of Product supplied to GSK. In the event
of any inconsistencies between the terms of the body of this Supply Agreement
and the Quality Obligations, the terms of the Supply Agreement shall govern.

     5.12 Reference Standard Product. Upon written request from GSK, ALLERGAN
shall supply a reasonable quantity of reference standard Product as needed by
GSK to complete government required testing.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       13

<PAGE>

6.   REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS OF GSK

     6.1 By ALLERGAN. ALLERGAN represents and warrants that:

          6.1.1 it is a corporation duly organized, validly existing and in good
standing under the laws of the Cayman Islands and has taken all necessary
action, including, without limitation, obtaining any necessary approval of its
board of directors, to execute and deliver this Supply Agreement;

          6.1.2 it has the corporate power and authority and the legal right to
own and operate its property and assets, to lease the property and assets it
operates under lease, and to carry on its business as it is now being conducted;

          6.1.3 it has full power and authority to enter into and perform this
Supply Agreement and does not require any shareholder action or approval, and
that this Supply Agreement constitutes and when executed will constitute, its
legal, valid and binding obligation, enforceable in accordance with its terms,
except as may be limited by bankruptcy and equitable principles limiting
specific performance;

          6.1.4 the execution, delivery and performance of this Supply Agreement
by ALLERGAN shall not constitute a breach or default, or an event which with the
giving of notice or passage of time or both would constitute a breach or
default, under any contract, instrument, law or other obligation to which it is
a party or by which it or any of its assets may be bound;

          6.1.5 it shall Manufacture and supply the Products in accordance with
the terms of this Supply Agreement including but not limited to the Quality
Obligations and shall comply with all Marketing Authorizations, Manufacturing
Authorizations, cGMPs and laws and regulations relevant to their Manufacture and
sale;

          6.1.6 all Products Manufactured, sold and shipped pursuant to this
Supply Agreement shall be Manufactured in accordance with all applicable
national and local environmental, health and safety laws and regulations in
effect at the time and place of Manufacture of the Products;

          6.1.7 all waste, including but not limited to all hazardous waste,
generated at the time of Manufacture of the Products shall be disposed of in
accordance with all applicable laws and regulations governing such matters in
the country of the Manufacturing Facilities; and

          6.1.8 unless otherwise required or prohibited by law, to the best of
its knowledge and in relation to the supply of Product under the terms of this
Supply Agreement, it complies with the requirements set out in Exhibit H,
Ethical Standards and Human Rights

     6.2 By GSK. GSK represents and warrants that:

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       14

<PAGE>

          6.2.1 it is a public limited company duly organized, validly existing
and in good standing under the laws of England has taken all necessary action,
including, without limitation, obtaining any necessary approval of its board of
directors, to execute and deliver this Supply Agreement,

          6.2.2 it has the corporate power and authority and the legal right to
own and operate its property and assets, to lease the property and assets it
operates under lease, and to carry on its business as it is now being conducted,

          6.2.3 it has full power and authority to enter into and perform this
Supply Agreement and does not require any shareholder action or approval, and
that this Supply Agreement constitutes and when executed will constitute, its
legal, valid and binding obligation, enforceable in accordance with its terms,
except as may be limited by bankruptcy and equitable principles limiting
specific performance, and

          6.2.4 the execution, delivery and performance of this Supply Agreement
by GSK shall not constitute a breach or default, or an event which with the
giving of notice or passage of time or both would constitute a breach or
default, under any contract, instrument, law or other obligation to which it is
a party or by which it or any of its assets may be bound.

     6.3 Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 6.1
AND IN THE LICENSE AGREEMENT, ALLERGAN MAKES NO, AND HEREBY DISCLAIMS ANY AND
ALL, REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
PRODUCTS, INCLUDING WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF ANY THIRD PARTY'S
PROPRIETARY RIGHTS.

     6.4. Restrictive Covenant of GSK.

          6.4.1 The Parties acknowledge that:

               (a) As of the Effective Date, neither GSK nor its Affiliates have
any current or future intention of making, having made, using, offer for sale or
importing a Competing Product (as defined in Section 6.4.2) in the Field of Use
in any country of the world; and

               (b) During the Term, GSK will obtain certain Confidential
Information of ALLERGAN relating to the development, manufacture and
commercialization Product, which is valuable and highly confidential to ALLERGAN
and critical to the competitive success of ALLERGAN's business worldwide.

          6.4.2 To the extent permitted under applicable law, during the Term
and for a period of *** after the expiration date of this Supply Agreement or
the effective date of the termination of this Supply Agreement for any reason
other than by GSK pursuant to Sections 8.2 or 8.3 (the "RESTRICTIVE PERIOD"),
neither GSK nor any Affiliate of GSK will manufacture, market,

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       15

<PAGE>

distribute, sell, promote, or detail any pharmaceutical product in the
Territory, which ***, other than Product (a "COMPETING PRODUCT") in the Field of
Use; provided, however that:

          6.4.3 If GSK or any of its Affiliates manufactures, initiates clinical
studies, markets, distributes, sells, promotes or details (collectively,
"COMMERCIALIZATION") a Competing Product *** during the Term GSK will (i) notify
ALLERGAN immediately upon becoming aware of such commercialization, and (ii)
cease commercialization of such Competing Product within *** after the date that
GSK became aware of such commercialization. If GSK does not cease such
commercialization within *** after becoming aware of such commercialization,
ALLERGAN, at any time thereafter, will have a right to terminate this Supply
Agreement and any other agreement between the Parties relating to Product in the
Other Territories, which termination by ALLERGAN of this Supply Agreement will
be deemed a termination of this Supply Agreement by ALLERGAN pursuant to Section
8.2. During the period between the date that GSK becomes aware of
commercialization of a Competing Product as provided in this Section 6.4.3 and
the earlier of the date on which GSK ceases such commercialization and
expiration of the Restrictive Period, GSK will pay to ALLERGAN *** of all of
GSK's or its Affiliates' net sales of such Competing Product (which net sales
will be calculated in the same manner that Net Sales are calculated in the
License Agreement). Notwithstanding the foregoing, if GSK or any of its
Affiliates has used ALLERGAN's Know-How or Confidential Information in
connection with the commercialization of a Competing Product as provided in this
Section 6.4.3, ALLERGAN will have the right to immediately terminate this Supply
Agreement and any other agreement between the Parties relating to Product in
other territories upon thirty (30) calendar days' prior written notice to GSK,
which termination by ALLERGAN will be deemed a termination of this Supply
Agreement by ALLERGAN pursuant to Section 8.2; and

          6.4.4 Notwithstanding anything contained in this Section 6.4, nothing
herein will, expressly or impliedly, preclude or restrict GSK (or any of its
Affiliates) in any way from, (i) acquiring a majority of the voting stock, or
all or substantially all of the assets of, a Business Entity (as defined in
6.4.4(a)) (ii) being acquired by a Business Entity; or (iii) merging,
amalgamating, taking over, or consolidating (or engaging in any similar
transaction) with a Business Entity (hereinafter, the actions referred to in
(i), (ii), and (iii) of this Section 6.4.4 are collectively referred to as
"Merger" or "MERGING").

               (a) The term "BUSINESS ENTITY" as used in this Section 6.4.4
means any Person which, at the time of such Merger, is commercializing (as such
term is defined in Section 6.4.1) a Competing Product ***, including, for
example, the Persons listed in Exhibit D.

               (b) In the event that GSK or any of its Affiliates Merges with a
Business Entity during the Term, GSK will divest or cause the divestiture of the
Competing Product being commercialized by the Business Entity within *** after
the date of the public announcement of such Merger ("MERGER DATE"). During such
*** period, (A) neither GSK nor any of its Affiliates will use any ALLERGAN
Know-How or Confidential Information in connection with the commercialization of
such Competing Product; and (B) GSK will continue to comply with the terms of
this Supply Agreement in all respects. If GSK does not divest or cause the
divesture of such Competing Product within *** after the Merger Date, ALLERGAN
may, at any time

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       16

<PAGE>

thereafter, shall have the right to terminate this Supply Agreement and any
other agreement between the parties relating to the Product in other
territories, which termination by ALLERGAN will be deemed a termination by
ALLERGAN pursuant to Section 8.2. In the event that GSK does not divest or cause
the divesture of such Competing Product within the *** period as provided in
this Section 6.4.4(b), GSK will pay to ALLERGAN *** of all of GSK's or its
successor's net sales of such Competing Product after such *** period (which net
sales will be calculated in the same manner that Net Sales are calculated
herein) and continuing until the earlier of the date on which GSK or its
successor divests such Competing Product or the expiration of the Restrictive
Period.

     6.5. People's Republic of China Matters. During the Term, GSK shall
promptly (i) provide ALLERGAN with copies of all correspondence and notices from
the Regulatory Authority in the Territory and (ii) inform ALLERGAN regarding any
changes in all applicable laws and regulations in the Territory, including
without limitation any applicable cGMPs, GQPs and GVPs provisions promulgated by
the Regulatory Authority in the Territory.

7.   INDEMNIFICATION AND INSURANCE

     7.1 Indemnification by ALLERGAN. Except in any case to the extent such
Liabilities (as defined below) are the responsibility of GSK under Section 7.2
(Indemnification by GSK), ALLERGAN shall indemnify, defend and hold GSK and its
Affiliates and their officers, directors, agents and employees (each and
collectively a "GSK INDEMNITEE") harmless from and against any claims, any and
all liabilities, damages, losses, costs and expenses, investigations, and
reasonable attorneys' fees incurred hereunder (each and collectively a
"LIABILITY") resulting from or arising out of a claim, suit, or proceeding
brought by a Third Party against a GSK Indemnitee arising out of or in
connection with

          7.1.1 the Manufacture of the Product in accordance with this Supply
Agreement,

          7.1.2 material breach by any ALLERGAN Indemnitee of any of ALLERGAN's
representations, warranties or obligations under this Supply Agreement,

          7.1.3 any willful misconduct or negligent act or omission of any
ALLERGAN in performing ALLERGAN's obligations under this Supply Agreement,
and/or

          7.1.4 a recall of the Product attributable to the Manufacture of the
Product by ALLERGAN.

     7.2 Indemnification by GSK. GSK shall indemnify, defend and hold harmless
ALLERGAN and its Affiliates and their officers, directors, agents and employees
(each and collectively an "ALLERGAN INDEMNITEE") from any Liabilities resulting
from a claim, suit or proceeding brought by a Third Party against an ALLERGAN
Indemnitee arising out of or in connection with (i) the material breach by any
GSK Indemnitee of any of its representations, warranties or obligations under
this Supply Agreement, (ii) any willful misconduct or negligent act or omission
of GSK in performing GSK's obligations under this Supply Agreement, or (iii) a
recall of the Product attributable solely to the negligence of GSK; except in
any case to the extent such

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       17

<PAGE>

Liabilities are the responsibility of ALLERGAN under Section 7.1
(Indemnification by ALLERGAN) of this Supply Agreement.

     7.3 Procedure. A party asserting a claim for indemnification under Section
5.9 or this Article 7 shall notify the indemnifying party in writing of any such
claims as follows: (a) within fifteen (15) days of receipt of service of process
of the commencement of suit, or (b) for non-litigated matters, within thirty
(30) days of receipt of notice thereof; provided, however, that failure to give
such notice shall not relieve the indemnifying party of its obligation to
provide indemnification hereunder except, if and to the extent that such failure
materially and adversely affects the ability of the indemnifying party to defend
the applicable claim, suit or proceeding. The indemnifying party shall be
entitled to assume sole control over the defense of any such claim at its own
cost and expense; provided, however, that the indemnitee shall have the right to
be represented by its own counsel at its own cost in such matters. Neither the
indemnifying party nor the indemnified party shall settle or dispose of any such
matter in any manner which would adversely affect the rights or interests of the
other party, require the other to be subject to an injunction, or require the
other to make any monetary payment, without the prior written consent of the
other party, which shall not be unreasonably withheld or delayed. Each party
shall reasonably cooperate with the other party and its counsel in the course of
the defense of any such suit, claim, or demand, such cooperation to include
without limitation using reasonable efforts to provide or make available
documents, information and witnesses.

     7.4 Insurance. Each party, at its own expense, shall maintain commercial
general/ product liability insurance including coverage for clinical trials with
a minimum limit of liability per occurrence of *** and *** in the annual
aggregate, or self insure for any such amounts, and, upon request, shall provide
the other party with a certificate of such insurance. Each party shall provide
at least thirty (30) days' notice to the other party prior to cancellation or
material change in the relevant party's insurance policy.

     7.5 Limitation of Liability. With respect to any claim by one party against
the other arising out of the performance or failure of performance of the other
party under this Supply Agreement, the parties expressly agree that the
liability of such party to the other party for such breach shall be limited
under this Supply Agreement or otherwise at law or equity to direct damages
only. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY
INDIRECT, SPECIAL, PUNITIVE, EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES,
INCLUDING WITHOUT LIMITATION, LOSS OF PROFIT, LOSS OF BUSINESS, LOSS OF SAVING
OR OTHER CONSEQUENTIAL LOSS. The limitations set forth in this Section 7.5 shall
not apply with respect to the obligations of ALLERGAN to indemnify GSK under
Section 7.1 or GSK to indemnify ALLERGAN under Section 7.2 in connection with a
Claim of a Third Party.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       18

<PAGE>

8.   TERM AND TERMINATION

     8.1 Term. The term of this Supply Agreement shall commence upon the
Effective Date and shall continue until the expiration or termination of the
License Agreement, unless extended by the mutual agreement of the parties or
terminated sooner pursuant to Sections 8.2, 8.3 or 8.4 (the "TERM").

     8.2 Termination Due to Breach. In the event of a material breach or default
of this Supply Agreement by a party hereto that is not cured within *** after
receipt of notice thereof from the other party, the party not in material breach
or default shall be entitled to terminate this Supply Agreement by giving
written notice to the other party, such termination to take effect immediately.
The right to terminate this Supply Agreement shall not be affected in any way by
a waiver of, or failure to take action with respect to, any previous default.

     8.3 Termination for Bankruptcy. Either party shall have the right to
terminate this Supply Agreement effective upon written notice to the other party
in the event the other party becomes insolvent or makes an assignment for the
benefit of creditors, or in the event bankruptcy or insolvency proceedings are
instituted against the other party or on the other party's behalf.

     8.4 Termination for Safety or Quality Reasons; Material Regulatory
Interruption. GSK will have the right to immediately terminate this Supply
Agreement upon providing thirty (30) calendar days' written notice to ALLERGAN,
if (a) there is a Material Regulatory Interruption (as defined in the License
Agreement) which has lasted for at least *** during the Term; or (b) GSK
reasonably determines, after consultation with ALLERGAN, that there are
significant safety or quality concerns relating to Product that GSK considers
(in accordance with its corporate policies and procedures) justifying that
Product not be sold in the Territory.

     8.5 Effect of Termination. Upon termination or expiration of this Supply
Agreement, each party shall promptly return to the other all Confidential
Information of the other party received solely under this Supply Agreement then
in its possession or in the possession of its Affiliates. Any Purchase Orders
received by ALLERGAN prior to the date of termination or expiration for delivery
within thirty (30) days of termination or expiration will be filled by ALLERGAN
and all other Purchase Orders shall be deemed cancelled; provided, however, that
if this Supply Agreement is terminated due to a breach by GSK. GSK shall have
one hundred and eighty (180) days after expiration or termination (other than
for breach by GSK) of this Supply Agreement to sell off any Product remaining in
its inventory or the inventory of its Affiliates or sublicensees on the date of
expiration or termination. After the expiration of such 180-day period, or in
the event of a termination of this Supply Agreement due to a breach by GSK,
ALLERGAN shall, at its sole option, (A) repurchase any or all of the Products
still in the inventory of GSK, its Affiliates and sublicensees at the Purchase
Price paid by GSK for such Products, in which case GSK shall deliver such
Product to an address notified to it by ALLERGAN, with shipping paid by GSK, or
(B) require GSK to destroy all such inventory at GSK's cost and certify such
destruction in writing no later than thirty (30) days after ALLERGAN's written
instruction to destroy such inventory.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       19

<PAGE>

     8.6 Survival. The provisions of Articles 6, 7, 9 and 10 and Sections 5.5,
5.6, 5.7, 5.8, 5.9, 8.5, 8.6 and 8.7 shall survive termination or expiration of
this Supply Agreement.

     8.7 No Waiver of Remedies. Termination of this Supply Agreement shall not
preclude either party from (a) claiming any other damages, compensation or
relief that it may be entitled to upon such termination, (b) any right to
receive any amounts accrued under this Supply Agreement prior to the termination
date but which are unpaid or become payable thereafter and (c) any right to
obtain performance of any obligation provided for in this Supply Agreement which
shall survive termination.

9. CONFIDENTIALITY

     9.1 Confidential Information. "CONFIDENTIAL INFORMATION" means, except as
provided below in this Section 9.1, the terms and conditions of this Supply
Agreement as well as confidential and proprietary information of a party,
whether in written, printed, verbal or electronic form, and whether disclosed
before or after the Effective Date, including research and development
activities, Product design details and specifications, technology and know-how,
sales and marketing plans, finances and business forecasts, procurement
requirements and vendor information, customer lists, personnel information and
strategic plans. Confidential Information will not include information that:

          9.1.1 is now, or hereafter becomes generally known or available to the
public through no act or failure to act on the part of the receiving party;

          9.1.2 was acquired by the receiving party before receiving such
information from the disclosing party through no breach of any duty of
confidentiality owed to the disclosing party and without restriction as to use
or disclosure;

          9.1.3 is hereafter rightfully furnished to the receiving party by a
Third Party without any breach of any duty of confidentiality owed to the
disclosing party and without restriction as to use or disclosure; or

          9.1.4 is information that the receiving party can document was
independently developed by the receiving party without any use of the disclosing
party's Confidential Information.

     9.2 Non-Disclosure of Confidential Information. Each party, when it is the
receiving party agrees: (i) to hold the disclosing party's Confidential
Information in strict confidence and not to disclose such Confidential
Information to any other Third Party without the prior written consent of the
disclosing party; and (ii) not to use, at any time following the Effective Date,
any Confidential Information of the disclosing party for its own benefit or for
the benefit of any Third Party for any purpose other than for the express
purposes permitted under this Supply Agreement or any other agreement between
the parties and/or their respective Affiliates relating to the Product; and
(iii) to limit the disclosure of Confidential Information to Permitted Persons.
For purposes hereof, the term "PERMITTED PERSON" shall mean the receiving
officers and employees of

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       20

<PAGE>

the receiving party or an Affiliate of the receiving party who have a need to
know in order to carry out the obligations under this Supply Agreement; provided
each has agreed in writing to maintain the confidentiality of the Confidential
Information in a manner no less protective than that set forth herein. The
receiving party shall use Confidential Information of a disclosing party solely
to exercise its rights and perform its obligations under this Supply Agreement
(including without limitation the right to use such Confidential Information in
connection with obtaining Marketing Authorizations in the Territory and to
disclose such Confidential Information to a Regulatory Authority in the
Territory), unless otherwise mutually agreed in writing. The receiving party
shall take the same degree of care with Confidential Information of a disclosing
party that it uses to protect its own confidential and proprietary information
of a similar nature and importance (but in any event no less than reasonable
care).

     9.3 Disclosure Required by Law. In the event a receiving party is required
to disclose Confidential Information of the disclosing party by any applicable
law, regulation, legal process, judicial order or by any applicable order or
requirement of any governmental or regulatory authority, it may do so only to
the extent required thereby; provided, however, that the receiving party will
(i) use reasonable efforts under the circumstances to provide advance notice to
the disclosing party of the required disclosure to allow the disclosing party an
opportunity to take steps to object to, prevent or limit its disclosure or
obtain a protective or other similar order with respect to the required
disclosure and (ii) restrict disclosure to only that portion of the Confidential
Information that is required to be disclosed.

     9.4 Remedies. The receiving party agrees that its obligations hereunder are
necessary and reasonable to protect the disclosing party's business interests
and that the unauthorized disclosure or use of the disclosing party's
Confidential Information would cause irreparable harm and significant injury,
the degree of which may be difficult to ascertain. The receiving party further
acknowledges and agrees that in the event of any actual or threatened breach of
this Supply Agreement, the disclosing party may have no adequate remedy at law
and accordingly, that the disclosing party will have the right to seek an
immediate injunction enjoining any breach or threatened breach of this Supply
Agreement, as well as the right to pursue any and all other rights and remedies
available at law or in equity for such breach or threatened breach.

     9.5 Return of Confidential Information. Upon the request of the disclosing
party, the receiving party will promptly return to the disclosing party or, upon
the disclosing party's written approval, destroy all material embodying
Confidential Information of the disclosing party in its possession or under its
control, including all copies thereof; provided that each party may, at such
party's expense, make and retain one (1) copy of the other party's Confidential
Information for legal archival purposes only.

     9.6 Disclosure of Agreement, Publicity and Publications. Except as
expressly provided otherwise in Section 9.3 (Disclosure Required by Law),
neither GSK nor ALLERGAN shall release to any Third Party or publish in any way
any non-public information with regard to the terms of this Supply Agreement or
concerning their cooperation without the prior written consent of the other
party, which consent will not be unreasonably withheld or delayed.
Notwithstanding the foregoing, ALLERGAN will issue a press release, public
statement or disclosure regarding this

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       21

<PAGE>

Supply Agreement. Such press release, public statement or disclosure will be
mutually agreed upon by the parties. Nothing in the foregoing, however, shall
prohibit a party from making disclosures to the extent deemed necessary under
applicable federal or state securities laws or any rule or regulation of any
nationally recognized securities exchange. In such event, however, the
disclosing party shall use good faith efforts to consult with the non-disclosing
party prior to such disclosure and shall request confidential treatment to the
extent available. Each party acknowledges and agrees that the other party shall
have the right to submit manuscripts relating to the Product for scientific
publications, A copy of any scientific abstract or manuscript of results from
any clinical trial that is submitted for publication will be provided by to the
other party within thirty (30) days after such submission. ALLERGAN acknowledges
and agrees that GSK may publish the results of clinical trials conducted by GSK
with the Product after the Effective Date on GSK's Clinical Trial Register and
that such publication will not be a breach of the confidentiality obligations
provided in Section 9.2. ALLERGAN agrees to cooperate with GSK in such effort as
further determined in accordance with the License Agreement, including using
commercially reasonable efforts to provide GSK with the protocols, results, data
and other information relating to all clinical trials conducted by GSK with the
Product in ALLERGAN's possession that GSK reasonably requires to be published on
GSK's Clinical Trial Register.

     9.7 Allergan Data Protections. GSK agrees and understands that Confidential
Information of ALLERGAN, including but not limited to data, disclosed to GSK is
very sensitive and ALLERGAN would not enter into this Supply Agreement without
additional assurances from GSK with respect to GSK's use of such Confidential
Information or possible disclosure of such Confidential Information to
ALLERGAN's competitors. Accordingly GSK will not use any such Confidential
Information in connection with any botulinum toxin research and/or development
other than as provided under this Supply Agreement.

     9.8 Termination. All obligations of confidentiality and non-use imposed
under this Article 9 will expire *** after the date of expiration or termination
of this Supply Agreement, except that Article 9 obligations of confidentiality
and non-use will continue thereafter with respect to manufacturing and
regulatory information, including without limitation filings with Regulatory
Authorities.

10. GENERAL PROVISIONS

     10.1 Integration/Modification. This Supply Agreement, together with the
License Agreement, is both a final expression of the parties' agreement and a
complete and exclusive statement with respect to all of its terms. The Exhibits
referred to in this Supply Agreement are incorporated herein and made a part of
this Supply Agreement by this reference. This Supply Agreement supersedes all
prior and contemporaneous agreements and communications, whether oral, written
or otherwise, concerning any and all matters contained herein; provided,
however, that the confidentiality provisions of Article 9 are in addition to and
do not supersede the terms and conditions of the Confidential Disclosure
Agreement between Allergan Inc, an Affiliate of ALLERGAN, and GlaxoSmithKline
Research & Development Limited, an Affiliate of GSK, dated October 6, 2004, and
any amendments thereto. No rights or licenses are granted or deemed granted
hereunder or in connection herewith other than those rights or licenses
expressly granted in this Supply Agreement or in the License Agreement. No trade
customs, courses of dealing or courses of performance by the parties shall be
relevant to modify, supplement or explain any

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       22

<PAGE>

term(s) used in this Supply Agreement. This Supply Agreement may not be modified
or supplemented by any purchase order (except as set forth herein), change
order, acknowledgment, order acceptance, standard terms of sale, invoice or the
like. This Supply Agreement may only be modified or supplemented in a writing
expressly stated for such purpose and signed by the parties to this Supply
Agreement.

     10.2 Relationship Between the Parties. The parties have no ownership
interest in the other and their relationship, as established by this Supply
Agreement, is solely that of independent contractors. This Supply Agreement does
not create any partnership, joint venture or similar business relationship
between the parties. No party is a legal representative of any other party, and
no party can assume or create any obligation, representation, warranty or
guarantee, express or implied, on behalf of any other party for any purpose
whatsoever.

     10.3. Non-Waiver. The failure of a party to exercise, enforce or insist
upon strict performance of any provision of this Supply Agreement, or any right
arising out of this Supply Agreement, shall neither impair that provision or
right nor constitute a waiver of that provision or right, in whole or in part,
and will not be construed to be a waiver of such right or provision, or a waiver
by a party to thereafter enforce such right or provision or any other right or
provision hereunder. No waiver shall be effective unless made in writing and
signed by the waiving party.

     10.4 Assignment. This Supply Agreement is binding upon and inures to the
benefit of the parties to it, and to their permitted successors and assigns. No
party may assign or delegate any or all of its rights or obligations under this
Supply Agreement without the prior written consent of the other party except to
an Affiliate. Any assignment or delegation, or any other transfer or change of
control by sale, acquisition, merger, or otherwise, or attempt at the same,
other than to an Affiliate, made in the absence of such prior written consent
shall be void and without effect; provided, however, that in the event of the
foregoing, such written consent shall not be unreasonably withheld. If a party
assigns this Supply Agreement to an Affiliate, such party will also promptly
inform the other party and guarantee the performance by its Affiliate of all of
such party's obligations under this Supply Agreement. Either party may, however,
with notice, but without consent and at its sole discretion, assign all of the
rights and obligations under this Supply Agreement (excluding however, with
regard to ALLERGAN, any of its rights under Section 6.4) to a Third Party in
connection with the transfer or sale of all or substantially all of its
business, or in the event of its merger or consolidation or a change of control
or similar transaction.

     10.5 No Third Party Beneficiaries. This Supply Agreement is neither
expressly nor impliedly made for the benefit of any Person other than those
executing it.

     10.6 Severability. If, for any reason, any portion of this Supply Agreement
is adjudicated invalid, unenforceable or illegal by a court of competent
jurisdiction, such adjudication shall not affect or impair, in whole or in part,
the validity, enforceability or legality of any remaining portions of this
Supply Agreement. All remaining portions shall remain in full force and effect
as if the original Supply Agreement had been executed without the invalidated,
unenforceable or illegal portion.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       23

<PAGE>

     10.7 Notices. Any notice to be given under this Supply Agreement must be in
writing and delivered either in person, by any method of mail (postage prepaid)
requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the party to be notified at its
address(es) given below, or at any address such party has previously designated
by prior written notice to the other. Notice shall be deemed sufficiently given
for all purposes upon the earlier of: (a) the date of actual receipt; (b) if
mailed, three (3) calendar days after the date of postmark; or (c) if delivered
by overnight courier, the next business day the overnight courier regularly
makes deliveries.

If to GSK:        Glaxo Group Limited
                  Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex,
                  UB6 0NN, England
                  Attention: Company Secretary
                  Telephone: (+44) 20 8047 5000
                  Facsimile: (+44) 20 8047 6912

With a copy to:   Legal Operations - GMS
                  GlaxoSmithKline
                  980 Great West Road
                  Brentford, Middlesex, TW8 9GS, UK

If to ALLERGAN:   Allergan Pharmaceuticals Ireland
                  Carrowberg, Castlebar Road
                  Westport Co.
                  Mayo Ireland
                  Attention: Colam O'Neil
                  Telephone No: 353 98 27125
                  Facsimile No: 353 98 27124

With a copy to:   Allergan, Inc.
                  2525 Dupont Drive
                  Irvine, California  92612 U.S.A.
                  Attention: General Counsel
                  Telephone: (714) 246-4658
                  Facsimile: (714) 246-6987

     10.8 Force Majeure. Without prejudice to any rights of GSK set out in the
License Agreement in relation to a Material Supply Interruption or Material
Regulatory Interruption, each party shall be excused from liability for the
failure or delay in performance of any obligation under this Supply Agreement by
reason of any event beyond such party's reasonable control which materially
impacts the performance of the relevant party's obligations under this Supply
Agreement including but not limited to acts of God, fire, flood, earthquake, or
other natural forces, war, terrorism, civil unrest, or any other event similar
to those enumerated above (a "FORCE MAJEURE EVENT"). Such excuse from liability
shall be effective only to the extent and duration of the Force Majeure Event
causing the failure or delay in performance and provided that the party

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       24

<PAGE>

has not caused such Force Majeure Event to occur. Notice of a party's failure or
delay in performance due to Force Majeure Event must be given to the other party
within *** after its occurrence. All delivery dates and performance deadlines
under this Supply Agreement that have been affected by the Force Majeure Event
shall be suspended for the duration of such Force Majeure Event.

     10.9 Disputes. If a dispute or controversy regarding any matter under this
Supply Agreement arises between the Parties which they are unable to resolve (a
"DISPUTE"), each of the Parties will (subject to any cure period as set forth in
this Supply Agreement), be entitled to submit to the other party written notice
of such Dispute, with such notice setting forth in reasonable detail the nature
of the Dispute (the "DISPUTE NOTICE"). For a period of thirty (30) calendar days
after the date of the receiving party's receipt of the Dispute Notice, the
Parties will seek to resolve such Dispute by good faith negotiation between the
President of GSK's Global Manufacturing and Supply Division for GSK or his/her
designee and the Senior Vice President, Global Technical Operations for ALLERGAN
or his/her designee. If at the end of such thirty (30) calendar day period the
Dispute remains unresolved, the Parties may seek relief for such Dispute using
any appropriate administrative or judicial mechanism which may be available,
subject to Section 10.11. The provisions of this Section 10.9 will not restrict
in any way the Parties' rights to seek preliminary injunctive or other equitable
relief from any court having jurisdiction.

     10.10 Legal Fees. If any party to this Supply Agreement resorts to any
legal action in connection with this Supply Agreement, the prevailing party
shall be entitled to recover reasonable fees of attorneys and other
professionals in addition to all court costs which that party may incur as a
result.

     10.11 Governing Law. Notwithstanding its place of execution or performance,
this Supply Agreement, and all claims arising out of or relating to this Supply
Agreement, shall be governed by and construed in accordance with the laws of the
State of New York, irrespective of its laws regarding choice or conflict of
laws. The Parties hereby agree that for the purposes of resolving any Disputes
hereunder, in accordance with Section 10.9, that the Parties hereby submit to
the exclusive jurisdiction of the courts of New York.

     10.12 Interpretation.

          (a) Captions & Headings. The captions and headings of clauses
contained in this Supply Agreement preceding the text of the articles, sections,
subsections and paragraphs hereof are inserted solely for convenience and ease
of reference only and shall not constitute any part of this Supply Agreement, or
have any effect on its interpretation or construction.

          (b) Singular & Plural. All references in this Supply Agreement to the
singular shall include the plural where applicable, and all references to gender
shall include both genders and the neuter.

          (c) Articles, Sections & Subsections. Unless otherwise specified,
references in this Supply Agreement to any article shall include all sections,
subsections, and paragraphs in such

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       25

<PAGE>

article; references in this Supply Agreement to any section shall include all
subsections and paragraphs in such sections; and references in this Supply
Agreement to any subsection shall include all paragraphs in such subsection.

          (d) Days. All references to days in this Supply Agreement shall mean
calendar days, unless otherwise specified.

          (e) Ambiguities. Ambiguities and uncertainties in this Supply
Agreement, if any, shall not be interpreted against either party, irrespective
of which party may be deemed to have caused the ambiguity or uncertainty to
exist.

          (f) Including. The word "including" or any variation thereof means
"including without limitation" and the word "including" or any variation thereof
will not be construed to limit any general statement which it follows to the
specific or similar items or matters immediately following it.

     10.13 Counterparts. This Supply Agreement may be executed in one or more
counterparts (which may be delivered by facsimile), each of which shall be
deemed an original document, and all of which, together with this writing, shall
be deemed one instrument.

     10.14 Further Assurances. Each party to this Supply Agreement shall, at its
own expense, furnish, execute, and deliver all documents and take all actions as
may reasonably be required to effect the terms and purposes of this Supply
Agreement.

     10.15 Non-Solicitation. The parties hereto recognize that each party has a
substantial interest in preserving and maintaining confidential its Confidential
Information hereunder. Each party hereto recognizes that certain of the other
party's employees, including those engaged in the activities contemplated by
this Supply Agreement may have access to such Confidential Information of the
other party. The parties hereto therefore agree not to solicit or otherwise
induce or attempt to induce for purposes of employment, any employees from the
other party involved in the activities contemplated by this Supply Agreement and
for a period of *** thereafter without the prior consent of the other party. For
the avoidance of doubt, the posting of open positions and other such general
recruiting efforts shall not be deemed to constitute direct solicitation.

     10.16 Performance by Affiliates. The parties recognize that each party may
perform some or all of its obligations under this Supply Agreement, subject to
the Change Control procedure, through Affiliates, provided, however, that each
party shall remain responsible for the performance by its Affiliates and shall
cause its Affiliates to comply with the provisions of this Supply Agreement in
connection with such performance. Each party hereby expressly waives any
requirement that the other party exhaust any right, power or remedy, or proceed
against an Affiliate, for any obligation or performance hereunder prior to
proceeding directly against such party.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       26

<PAGE>

     10.17 Compliance with Laws. Each party shall at all times comply with all
applicable laws and regulations in the country of Manufacture and the Territory
relating to its activities under this Supply Agreement.

     10.18 No Use of Names. Except as otherwise required under applicable law,
or as otherwise permitted under this Supply Agreement, neither party will use
the name of the other in its advertising, press releases or promotional
materials without the prior written consent of such other party.

     IN WITNESS WHEREOF, the parties, intending to be bound hereby, have
executed this Supply Agreement by their duly authorized representatives as of
the date first above written.

ALLERGAN PHARMACEUTICALS               GLAXO GROUP LIMITED
IRELAND

By: /s/ COLAM O'NEIL                   By: /s/ LORRAINE DAY
    ---------------------------------      ------------------------------------
Name: Colam O'Neil                     Name: Lorraine Day
      -------------------------------        ----------------------------------
                                             For and on behalf of
                                             Edinburgh Pharmaceutical Industries
                                             Limited

Title: Director                        Title: Corporate Director
       ------------------------------         ---------------------------------

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       27

<PAGE>

                                    EXHIBIT A

                 FORM OF CERTIFICATE OF ANALYSIS AND COMPLIANCE

ALLERGAN PHARMACEUTICALS IRELAND
WESTPORT CO. MAYO IRELAND
Telephone No: 353 98 27125
Facsimile No: 353 98 27124
Web Site: www.allergan.com

                             ALLERGAN BOTOX IRELAND
                     CERTIFICATE OF ANALYSIS AND COMPLIANCE
                          (PEOPLE'S REPUBLIC OF CHINA)

MATERIAL: BOTOX(R) 100 Units                         EXPIRY DATE.: _____________

BATCH NO.: _______________________________________   FORMULA NO.: ______________

DATE OF FILL: ____________________________________   MATERIAL NO.: _____________

PRODUCTION LINE: _________________________________

DATE OF LAST VALID POTENCY TEST (MFG DATE): ______

CUSTOMER PRODUCT CODE: ___________________________

MARKETING AUTHORISATION NUMBER: __________________

<TABLE>
<CAPTION>
TEST   LIMITS   RESULTS
----   ------   -------
<S>    <C>      <C>
***    ***
</TABLE>

*    Expiry date is calculated from the date of valid potency test plus approved
     shelf life.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

<PAGE>

BATCH NO.: _____                                            DATE OF FILL: ______

I HEREBY CERTIFY THAT THE BATCH OR BATCHES OF API USED TO MANUFACTURE THIS BATCH
OF DRUG PRODUCT HAS BEEN MANUFACTURED, PACKED AND QUALITY CONTROLLED AT THE
REGISTERED SITES(S) IN FULL COMPLIANCE WITH CGMP REQUIREMENTS INCLUDING THOSE OF
FDA, ICHQ7A AND WITH THE REGISTERED MANUFACTURING PROCESS AND WITH THE
SPECIFICATIONS REGISTERED IN THE MARKETING AUTHORISATION OF THE PRODUCT AND ANY
OTHER APPLICABLE CONDITIONS IN ACCORDANCE WITH THE PEOPLE'S REPUBLIC OF CHINA
SFDA REGULATION NO. 9 ISSUED BY THE SFDA ON 18 JUNE 1999. THE BATCH PROCESSING,
PACKAGING AND ANALYSIS RECORDS WERE REVIEWED AND FOUND TO BE IN COMPLIANCE WITH
THE CGMP REQUIREMENTS.

SIGNED:                                 DATE:
        -----------------------------         ----------------------------------
NAME:
     --------------------------------
TITLE:
       ------------------------------

I HEREBY CERTIFY THAT THE ABOVE INFORMATION IS AUTHENTIC AND ACCURATE. THIS
BATCH OF PRODUCT HAS BEEN MANUFACTURED, PACKED AND QUALITY CONTROLLED AT THE
ABOVE MENTIONED SITES(S) IN FULL COMPLIANCE WITH THE GMP REQUIREMENTS OF THE
EUROPEAN COMMUNITY AND WITH THE SPECIFICATIONS REGISTERED IN THE MARKETING
AUTHORISATION OF THE PRODUCT AND ANY OTHER APPLICABLE CONDITIONS IN ACCORDANCE
WITH THE PEOPLE'S REPUBLIC OF CHINA SFDA REGULATION NO. 9 ISSUED BY THE SFDA ON
18 JUNE 1999. THE BATCH PROCESSING, PACKAGING AND ANALYSIS RECORDS WERE REVIEWED
AND FOUND TO BE IN COMPLIANCE WITH THE GMP REQUIREMENTS.

EXCEPTIONS (DEVIATIONS) NOTED DURING MANUFACTURING, PACKAGING (IF APPLICABLE)
AND TESTING:

___ NO

___ YES. EXCEPTION REPORT NUMBERS LISTED BELOW AND ATTACH REPORT.

THE ABOVE DRUG PRODUCT HAS BEEN RELEASED FOR SHIPMENT TO __________________.

SIGNED:                                 DATE:
        -----------------------------         ----------------------------------
NAME:
     --------------------------------
TITLE:
       ------------------------------

(BOTOX(R) LOGO)              DIRECTORS. Steve Goggins; Douglas S. Ingram (U.S.);
BOTULINUM TOXIN TYPE A                  Sue Jean Lin (U.S.); Colem O'Neil;
Purified Neurotoxin Complex             Patrick O'Donnell.

                                        Registered Dublin No. E 1969.
                                        Registered Cayman Islands No. CR-105719.
                                        V.A.T. No. IE 9Z68154G

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

<PAGE>

                                    EXHIBIT B

                             FORM OF PURCHASE ORDER

              (To be supplied within 10 days after Effective Date)

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT C

                           TESTING METHODS FOR PRODUCT

***

                             TESTING METHODS FOR API

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT D

                              ALLERGAN COMPETITORS

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT E

                                WIRE INSTRUCTIONS

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT F

                               QUALITY OBLIGATIONS

1.   OBJECT OF THIS EXHIBIT

     This Exhibit defines the quality obligations to be applied by ALLERGAN and
     GSK in addition to those defined in the Supply Agreement.

     More detailed work processes and definition of responsibilities will be the
     subject of a separate operating policy which will be agreed prior to the
     transfer of the Regulatory Approval in the Territory to GSK.

2.   RESPONSIBLE PERSONS AND CGMP

     2.1  GSK and ALLERGAN will each designate senior quality staff to act as
          points of contact for the purpose of this Exhibit.

     2.2  ALLERGAN will designate an employee who shall have the necessary
          experience, qualifications, independence and authority and who will
          supervise overall quality assurance of the Manufacture of the Product
          (the "Senior Quality Manager"). This includes ensuring that the terms
          of this Exhibit and the Supply Agreement are communicated to the
          relevant ALLERGAN staff, or staff of ALLERGAN's Authorised
          Sub-Contractors (including API manufacturers), and ensuring operations
          are performed in strict accordance with cGMP, applicable Regulatory
          Approvals and any other applicable law.

     2.3  The ALLERGAN Senior Quality Manager will collect and review the data
          necessary to make recommendations on the disposition of Materials and
          Lots of Product from the Manufacturing Facility. The ALLERGAN Senior
          Quality Manager shall establish procedures for providing the
          Certificate of Analysis and Compliance and such other information as
          is necessary under cGMP, the Regulatory Approvals and applicable law
          for GSK to make the final decision on release of Product for sale in
          the Territory.

     2.4  GSK will designate an employee in the Territory who shall have the
          necessary experience, qualifications, independence and authority and
          who will supervise acceptance, testing and final release of the
          Product for sale in the Territory. This includes ensuring that the
          terms of this Exhibit and the Supply Agreement are communicated to the
          relevant GSK staff, or staff of GSK's Authorised Sub-Contractors
          (including any Third Party that will test the Product in the
          Territory), and ensuring such operations are performed in strict
          accordance with cGMP, applicable Regulatory Approvals and any other
          applicable law.

3.   REFERENCE MATERIALS

     3.1  Testing will be performed only with reference Materials that are
          traceable to pharmacopoeial or other internationally recognised
          standards. Use of secondary

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

          reference Materials must be in accordance with ALLERGAN's validated
          process for preparation, storage, maintenance and record keeping for
          such secondary reference standards.

     3.2  ALLERGAN will supply GSK with the approved and certified reference
          Materials which are required by GSK in order to carry out testing of
          the Products in the Territory.

4.   STORAGE AND SHIPPING

     4.1  Up to the delivery of Product to GSK's carrier, ALLERGAN will ensure
          Materials and Product are shipped and stored such that the
          environmental conditions are maintained, monitored and recorded as
          appropriate to meet the conditions specified on the label, cGMP and
          any other regulatory requirements.

     4.2  From and after the delivery of Product to GSK's carrier, GSK will
          ensure Product is shipped and stored such that the environmental
          conditions are maintained, monitored and recorded as appropriate to
          meet the conditions specified on the label, cGMP and any other
          regulatory requirements.

5.   NON-CONFORMANCES AND MAJOR PREVENTATIVE ACTIONS

     5.1  ***

     5.2  ALLERGAN will report to GSK in a timely manner any major improvement
          actions that are required to prevent discontinuation of Manufacture,
          importation or selling of the Product or that are required to ensure
          that recall or disposal of the Product is not required.

     5.3  GSK shall promptly report in writing to ALLERGAN regarding any Product
          that does not test to Specifications or that is rejected by GSK. GSK
          shall also provide a written report, not less often than ***.

     5.4  If GSK identifies (for example, from customer complaints, or Product
          non-conformances) that improvement actions are required to operational
          procedures or the Manufacturing Facilities, ALLERGAN must investigate
          the matter and correct any issues ALLERGAN identifies as necessary to
          meet the requirements of cGMP or address Product non-conformances.

6.   ***

7.   USE OF THIRD PARTY CONTRACTORS

     7.1  For the purposes of this Exhibit F, the term "Authorised
          Sub-Contractors" means third party contractors engaged by (i)
          ALLERGAN, via validated procedures, to perform any part of ALLERGAN's
          cGMP obligations under the License Agreement, Supply Agreement or this
          Exhibit (including, but not limited to, laboratory testing services)
          or (ii) GSK, via validated procedures, to perform any part of GSK's
          testing with respect to the Product in the Territory.

     7.2  ALLERGAN and GSK may only use Authorised Sub-contractors. To the
          extent required by applicable law, any change to or appointment of a
          new Authorised Sub-

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

          contractors may not occur until GSK has obtained approval from the
          Regulatory Authority for a change to the Regulatory Approval in the
          Territory.

     7.3  Any reference to responsibilities of a Party in this Exhibit is to be
          read as applying to any Authorised Sub-contractor for any activities
          that they perform on behalf of that Party. Each Party is responsible
          for putting in place and enforcing appropriate management systems and
          contractual agreements with the Authorised Sub-contractor to ensure
          these responsibilities are met.

     7.4  The contract with the Authorised Sub-contractor must specifically
          include ***.

8.   RETENTION SAMPLES

     ALLERGAN will take and retain representative samples of each Lot of
     Materials and Products sufficient to comply with cGMP.

9.   COMPLAINT MANAGEMENT

     9.1  GSK will manage all communications with in the Territory and pass
          Manufacturing related customer complaints to ALLERGAN for
          investigation and testing.

     9.2  ***

     9.3  ***

     9.4  Complaints that indicate an Adverse Drug Experience has occurred shall
          be communicated and resolved in accordance with the Pharmacovigilance
          Agreement.

10.  STABILITY PROGRAM

     10.1 ALLERGAN will conduct an ongoing stability program in accordance with
          a validated procedure including storage conditions and testing
          protocols for the Product necessary to meet the requirements of cGMP,
          Regulatory Approvals and applicable law. ICH storage conditions will
          be used, unless agreed otherwise by the parties.

     10.2 Where Change Control identifies a need for additional supporting
          stability data on validation batches, ALLERGAN will consult with GSK
          on any additional programme and testing protocols.

     10.3 Any non-conforming stability results or adverse trends must be
          reviewed by ALLERGAN in a timely manner and if confirmed, ***.

11.  ANNUAL PRODUCT QUALITY REVIEWS

     11.1 ALLERGAN will conduct an Annual Product Quality Review for each
          Product in the Territory on an annual basis ***. GSK and ALLERGAN
          shall agree on the format, content and schedule for Annual Product
          Quality Review reports. ALLERGAN will review the data and identify to
          GSK changes or improvements that ALLERGAN believes may be desirable as
          part of the Annual Product Quality Review report.

     11.2 GSK will review the data supplied and may make recommendations with
          respect to any changes/improvements that GSK believes are necessary or
          desirable. Any such changes

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

          or improvements adopted by ALLERGAN shall be implemented under
          appropriate Change Control procedures.

     11.3 Items to be covered by the Annual Product Quality Review typically
          include, but are not limited to, changes to facilities, equipment,
          process or specification, non-conformances, complaints, rejections,
          reworks, Product returns, recalls, trends in key control parameters,
          summaries and trends of stability data, and summaries of validation
          activities.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT G

             EXAMPLE OF PRICE ADJUSTMENT AND RECONCILIATION PROCESS

<TABLE>
<CAPTION>
YEAR ONE   YEAR TWO   YEAR THREE   YEAR FOUR   YEAR FIVE
--------   --------   ----------   ---------   ---------
<S>        <C>        <C>          <C>         <C>
   ***        ***         ***         ***         ***
</TABLE>

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

                                    EXHIBIT H

                       ETHICAL STANDARDS AND HUMAN RIGHTS

     (A)  ALLERGAN does not employ engage or otherwise use any child labour in
          circumstances such that the tasks performed by any such child labour
          could reasonably be foreseen to cause either physical or emotional
          impairment to the development of such child;

     (B)  ALLERGAN does not use forced labour in any form (prison, indentured,
          bonded or otherwise) and staff are not required to lodge papers or
          deposits on starting work;

     (C)  ALLERGAN provides a safe and healthy workplace, presenting no
          immediate risks to its staff. Any housing provided by ALLERGAN to its
          workers is safe for habitation. ALLERGAN provides access to clean
          water, food, and emergency healthcare to its workers in the event of
          accidents or incidents at ALLERGAN's workplace;

     (D)  ALLERGAN does not discriminate against any worker on any ground
          (including race, religion, disability or gender). ALLERGAN does not
          engage in or support the use of corporal punishment, mental, physical,
          sexual or verbal abuse and does not use cruel or abusive disciplinary
          practices in the workplace;

     (E)  ALLERGAN pays each employee at least the minimum wage, or a fair
          representation of the prevailing industry wage, (whichever is the
          higher) and provides each employee with all legally mandated benefits;

     (F)  ALLERGAN complies with the laws on working hours and employment rights
          in the countries in which it operates;

     (G)  ALLERGAN does not engage in any activities which may cause health and
          safety harm to those living in the vicinity to its operations; and

     (H)  ALLERGAN is responsible for controlling its own supply chain and
          agrees that it shall encourage compliance with ethical standards and
          human rights by any subsequent supplier of goods or services used in
          the Manufacture of the Product.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]